PKR
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Y Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Log-Odds: Y Sites / Y Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A5A3E0 | Y940 | Sugiyama | POTEF A26C1B | ALDFEQEMATVAsSSSLEKsyELPDGQVItIGNERFRCPEA |
| O60841 | S182 | Sugiyama | EIF5B IF2 KIAA0741 | DGsEEDEDNsKKIKERsRINssGEsGDEsDEFLQsRKGQKK |
| P04637 | S392 | SIGNOR|iPTMNet|EPSD|PSP | TP53 P53 | KKGQstsRHKKLMFKtEGPDsD___________________ |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P05198 | S49 | GPS6|ELM|iPTMNet|EPSD|PSP | EIF2S1 EIF2A | EMGAYVSLLEYNNIEGMILLsELsRRRIRSINKLIRIGRNE |
| P05198 | S52 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | EIF2S1 EIF2A | AYVSLLEYNNIEGMILLsELsRRRIRSINKLIRIGRNECVV |
| P06493 | Y4 | SIGNOR|EPSD|PSP | CDK1 CDC2 CDC28A CDKN1 P34CDC2 | _________________MEDyTKIEKIGEGtyGVVyKGRHK |
| P14618 | S37 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | QLHAAMADTFLEHMCRLDIDsPPItARNtGIICtIGPAsRs |
| P19525 | S242 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | EIF2AK2 PKR PRKR | LNSSSLLMNGLRNNQRKAKRsLAPRFDLPDMKEtKYtVDKR |
| P19525 | S418 | Sugiyama | EIF2AK2 PKR PRKR | ITKGVDYIHSKKLIHRDLKPsNIFLVDtKQVKIGDFGLVts |
| P19525 | S456 | Sugiyama | EIF2AK2 PKR PRKR | VtsLKNDGKRtRSKGtLRyMsPEQIssQDYGKEVDLYALGL |
| P19525 | S461 | Sugiyama | EIF2AK2 PKR PRKR | NDGKRtRSKGtLRyMsPEQIssQDYGKEVDLYALGLILAEL |
| P19525 | S462 | Sugiyama | EIF2AK2 PKR PRKR | DGKRtRSKGtLRyMsPEQIssQDYGKEVDLYALGLILAELL |
| P19525 | S6 | PSP | EIF2AK2 PKR PRKR | _______________MAGDLsAGFFMEELNTYRQKQGVVLK |
| P19525 | S83 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | EIF2AK2 PKR PRKR | AKNAAAKLAVEILNKEKKAVsPLLLtttNssEGLsMGNyIG |
| P19525 | T255 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | EIF2AK2 PKR PRKR | NQRKAKRsLAPRFDLPDMKEtKYtVDKRFGMDFKEIELIGS |
| P19525 | T258 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | EIF2AK2 PKR PRKR | KAKRsLAPRFDLPDMKEtKYtVDKRFGMDFKEIELIGSGGF |
| P19525 | T425 | Sugiyama | EIF2AK2 PKR PRKR | IHSKKLIHRDLKPsNIFLVDtKQVKIGDFGLVtsLKNDGKR |
| P19525 | T446 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | EIF2AK2 PKR PRKR | KQVKIGDFGLVtsLKNDGKRtRSKGtLRyMsPEQIssQDYG |
| P19525 | T451 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP|Sugiyama | EIF2AK2 PKR PRKR | GDFGLVtsLKNDGKRtRSKGtLRyMsPEQIssQDYGKEVDL |
| P19525 | T529 | Sugiyama | EIF2AK2 PKR PRKR | KKEKTLLQKLLSKKPEDRPNtSEILRTLTVWKKsPEKNERH |
| P19525 | T88 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | EIF2AK2 PKR PRKR | AKLAVEILNKEKKAVsPLLLtttNssEGLsMGNyIGLINRI |
| P19525 | T89 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | EIF2AK2 PKR PRKR | KLAVEILNKEKKAVsPLLLtttNssEGLsMGNyIGLINRIA |
| P19525 | T90 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | EIF2AK2 PKR PRKR | LAVEILNKEKKAVsPLLLtttNssEGLsMGNyIGLINRIAQ |
| P19525 | Y101 | SIGNOR|iPTMNet|EPSD|PSP | EIF2AK2 PKR PRKR | AVsPLLLtttNssEGLsMGNyIGLINRIAQKKRLTVNYEQC |
| P19525 | Y162 | SIGNOR|iPTMNet|EPSD|PSP | EIF2AK2 PKR PRKR | YSIGTGSTKQEAKQLAAKLAyLQILSEETSVKSDYLSSGSF |
| P19525 | Y293 | SIGNOR|iPTMNet|EPSD|PSP | EIF2AK2 PKR PRKR | IGSGGFGQVFKAKHRIDGKTyVIKRVKYNNEKAEREVKALA |
| P19525 | Y454 | Sugiyama | EIF2AK2 PKR PRKR | GLVtsLKNDGKRtRSKGtLRyMsPEQIssQDYGKEVDLYAL |
| P25963 | S32 | SIGNOR|iPTMNet|EPSD | NFKBIA IKBA MAD3 NFKBI | AMEGPRDGLKKERLLDDRHDsGLDsMKDEEyEQMVKELQEI |
| P26038 | S576 | Sugiyama | MSN | YKtLRQIRQGNTKQRIDEFEsM___________________ |
| P54105 | S102 | Sugiyama | CLNS1A CLCI ICLN | VNAKFEEEsKEPVADEEEEDsDDDVEPITEFRFVPSDKSAL |
| P60709 | Y240 | Sugiyama | ACTB | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62736 | Y242 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P63261 | Y240 | Sugiyama | ACTG1 ACTG | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| P63267 | Y241 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P68032 | Y242 | Sugiyama | ACTC1 ACTC | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P68133 | Y242 | Sugiyama | ACTA1 ACTA | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| Q13263 | S473 | PSP | TRIM28 KAP1 RNF96 TIF1B | sGDDPyssAEPHVsGVKRsRsGEGEVsGLMRKVPRVsLERL |
| Q15080 | S67 | Sugiyama | NCF4 SH3PXD4 | TKGGSKYLIYRRYRQFHALQsKLEERFGPDSKSSALACTLP |
| Q15172 | S28 | SIGNOR|iPTMNet|EPSD|PSP | PPP2R5A | AGAASAAISASEKVDGFTRKsVRKAQRQKRsQGssQFRsQG |
| Q15637 | S80 | Sugiyama | SF1 ZFM1 ZNF162 | DLTRKLRtGDLGIPPNPEDRsPsPEPIyNsEGKRLNTREFR |
| Q15637 | S82 | Sugiyama | SF1 ZFM1 ZNF162 | TRKLRtGDLGIPPNPEDRsPsPEPIyNsEGKRLNTREFRTR |
| Q562R1 | Y241 | Sugiyama | ACTBL2 | ALDFEQEMVRAAAssSPERsyELPDGQVItIGNERFRCPEA |
| Q6PCE3 | S175 | Sugiyama | PGM2L1 BM32A | PFVPYAVQKLKAVAGVMItAsHNRKEDNGYKVYWETGAQIT |
| Q6S8J3 | Y940 | Sugiyama | POTEE A26C1A POTE2 | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| Q8IWX8 | S817 | Sugiyama | CHERP DAN26 SCAF6 | QSRSRSKSYSPGRRRRsRsRsPtPPssAGLGsNsAPPIPDS |
| Q8IWX8 | T819 | Sugiyama | CHERP DAN26 SCAF6 | RSRSKSYSPGRRRRsRsRsPtPPssAGLGsNsAPPIPDSRL |
| Q8NFD5 | S1744 | Sugiyama | ARID1B BAF250B DAN15 KIAA1235 OSA2 | ALDTINILLYDDSTVATFNLsQLSGFLELLVEYFRKCLIDI |
| Q8TAM6 | S280 | Sugiyama | ERMN KIAA1189 | TISYRKIRKGNTKQRIDEFEsMMHL________________ |
| Q96EZ8 | S282 | Sugiyama | MCRS1 INO80Q MSP58 | YLLEDQTVQPLPKGDQVLNFsDAEDLIDDSKLKDMRDEVLE |
| Q96G46 | T273 | Sugiyama | DUS3L | GAPRQENCGAQQVPAGPGtstPPssPVRtCGPLtDEDVVRL |
| Q9BYX7 | Y240 | Sugiyama | POTEKP ACTBL3 FKSG30 | ALDSEQEMAMAASSSSVEKsyELPDGQVItIGNERFRCPEA |
| Q9H3R0 | S918 | SIGNOR|PSP | KDM4C GASC1 JHDM3C JMJD2C KIAA0780 | RVMAVTSQTFYEVMFDDGSFsRDTFPEDIVSRDCLKLGPPA |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Axon guidance | R-HSA-422475 | 2.599909e-11 | 10.585 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 3.609003e-10 | 9.443 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 9.777338e-10 | 9.010 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 5.114626e-09 | 8.291 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 8.508446e-08 | 7.070 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 8.556436e-08 | 7.068 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.270319e-07 | 6.896 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 4.905525e-07 | 6.309 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 9.165134e-07 | 6.038 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 1.213174e-06 | 5.916 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.367893e-06 | 5.864 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 2.481708e-06 | 5.605 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 3.102827e-06 | 5.508 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 3.574619e-06 | 5.447 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 3.611859e-06 | 5.442 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 3.785962e-06 | 5.422 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 4.334007e-06 | 5.363 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 5.138349e-06 | 5.289 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 5.541638e-06 | 5.256 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 6.877624e-06 | 5.163 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 8.161455e-06 | 5.088 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 7.938043e-06 | 5.100 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 9.517060e-06 | 5.021 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 1.003412e-05 | 4.999 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 1.178206e-05 | 4.929 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 2.045235e-05 | 4.689 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 2.045235e-05 | 4.689 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 2.045235e-05 | 4.689 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 2.045235e-05 | 4.689 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.963053e-05 | 4.707 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 2.101450e-05 | 4.677 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 2.172446e-05 | 4.663 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 2.535090e-05 | 4.596 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.982798e-05 | 4.525 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 4.360155e-05 | 4.360 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 5.272778e-05 | 4.278 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 6.540869e-05 | 4.184 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 7.354997e-05 | 4.133 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 7.944266e-05 | 4.100 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 9.079882e-05 | 4.042 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 1.113193e-04 | 3.953 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 1.168453e-04 | 3.932 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 1.310144e-04 | 3.883 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 1.433357e-04 | 3.844 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.620120e-04 | 3.790 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 1.620120e-04 | 3.790 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 1.677674e-04 | 3.775 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 1.641193e-04 | 3.785 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.698274e-04 | 3.770 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 1.935771e-04 | 3.713 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.920185e-04 | 3.717 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 1.986603e-04 | 3.702 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 2.387791e-04 | 3.622 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 2.410377e-04 | 3.618 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 2.706247e-04 | 3.568 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 2.766538e-04 | 3.558 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 2.800224e-04 | 3.553 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 2.812747e-04 | 3.551 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 3.081691e-04 | 3.511 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 3.045295e-04 | 3.516 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 3.878678e-04 | 3.411 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 4.163765e-04 | 3.381 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 4.022376e-04 | 3.396 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 4.179473e-04 | 3.379 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 4.207265e-04 | 3.376 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 4.532036e-04 | 3.344 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 4.362171e-04 | 3.360 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 4.812196e-04 | 3.318 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 5.241929e-04 | 3.281 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 6.351193e-04 | 3.197 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 6.619100e-04 | 3.179 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 7.073755e-04 | 3.150 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 6.748826e-04 | 3.171 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 8.050293e-04 | 3.094 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 8.160095e-04 | 3.088 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 8.564807e-04 | 3.067 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 8.564807e-04 | 3.067 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 8.564807e-04 | 3.067 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 8.103548e-04 | 3.091 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 8.575257e-04 | 3.067 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 9.597734e-04 | 3.018 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 9.715369e-04 | 3.013 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 9.715369e-04 | 3.013 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 9.307808e-04 | 3.031 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 9.307808e-04 | 3.031 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.017184e-03 | 2.993 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 1.130888e-03 | 2.947 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 1.073582e-03 | 2.969 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 1.100259e-03 | 2.959 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 1.073582e-03 | 2.969 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 1.255866e-03 | 2.901 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 1.330578e-03 | 2.876 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.347605e-03 | 2.870 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 1.347605e-03 | 2.870 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 1.468280e-03 | 2.833 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.428752e-03 | 2.845 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 1.468280e-03 | 2.833 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 1.468280e-03 | 2.833 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 1.385154e-03 | 2.859 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.611272e-03 | 2.793 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 1.628201e-03 | 2.788 | 1 | 1 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 1.611272e-03 | 2.793 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 1.614776e-03 | 2.792 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 1.614776e-03 | 2.792 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 1.512939e-03 | 2.820 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 1.628201e-03 | 2.788 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 1.632058e-03 | 2.787 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.637804e-03 | 2.786 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.642697e-03 | 2.784 | 0 | 0 |
| Protein folding | R-HSA-391251 | 1.914807e-03 | 2.718 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 1.924907e-03 | 2.716 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 1.982788e-03 | 2.703 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 1.982788e-03 | 2.703 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 2.249522e-03 | 2.648 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 2.264458e-03 | 2.645 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 2.321138e-03 | 2.634 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 2.347033e-03 | 2.629 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 2.387689e-03 | 2.622 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 2.387689e-03 | 2.622 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 2.387689e-03 | 2.622 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 2.387689e-03 | 2.622 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 2.670018e-03 | 2.573 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 2.670018e-03 | 2.573 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 2.783711e-03 | 2.555 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 2.661200e-03 | 2.575 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 2.614804e-03 | 2.583 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 2.577435e-03 | 2.589 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 2.851811e-03 | 2.545 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 2.885212e-03 | 2.540 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 3.013085e-03 | 2.521 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 3.095116e-03 | 2.509 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 3.726692e-03 | 2.429 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 3.978423e-03 | 2.400 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 3.987524e-03 | 2.399 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 4.023073e-03 | 2.395 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 4.482984e-03 | 2.348 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 4.482984e-03 | 2.348 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 4.482984e-03 | 2.348 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 4.482984e-03 | 2.348 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 4.482984e-03 | 2.348 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 4.069078e-03 | 2.391 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 4.103562e-03 | 2.387 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 4.182445e-03 | 2.379 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 4.103562e-03 | 2.387 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 4.103562e-03 | 2.387 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 4.430707e-03 | 2.354 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 4.558244e-03 | 2.341 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 4.607500e-03 | 2.337 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 4.631195e-03 | 2.334 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.749791e-03 | 2.323 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 4.897806e-03 | 2.310 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 5.173228e-03 | 2.286 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 5.178358e-03 | 2.286 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 5.404676e-03 | 2.267 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 5.847375e-03 | 2.233 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 5.847375e-03 | 2.233 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 5.345214e-03 | 2.272 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 5.764658e-03 | 2.239 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 5.926323e-03 | 2.227 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 6.401388e-03 | 2.194 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 6.591974e-03 | 2.181 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 6.740831e-03 | 2.171 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 6.740831e-03 | 2.171 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 6.740831e-03 | 2.171 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 6.792594e-03 | 2.168 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 6.792594e-03 | 2.168 | 0 | 0 |
| Kinesins | R-HSA-983189 | 7.142063e-03 | 2.146 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 8.401444e-03 | 2.076 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 8.401444e-03 | 2.076 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 8.401444e-03 | 2.076 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 8.401444e-03 | 2.076 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 8.401444e-03 | 2.076 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 8.071984e-03 | 2.093 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 8.401444e-03 | 2.076 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 8.401444e-03 | 2.076 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 8.401444e-03 | 2.076 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 7.769947e-03 | 2.110 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 8.093679e-03 | 2.092 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 8.579512e-03 | 2.067 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 9.325872e-03 | 2.030 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 9.506283e-03 | 2.022 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 9.723236e-03 | 2.012 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 9.723236e-03 | 2.012 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 9.986724e-03 | 2.001 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 1.024350e-02 | 1.990 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 1.024350e-02 | 1.990 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 1.045269e-02 | 1.981 | 1 | 0 |
| Downstream signal transduction | R-HSA-186763 | 1.055930e-02 | 1.976 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 1.129130e-02 | 1.947 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 1.129130e-02 | 1.947 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 1.129130e-02 | 1.947 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.141015e-02 | 1.943 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.258443e-02 | 1.900 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 1.261750e-02 | 1.899 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 1.491590e-02 | 1.826 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 1.491590e-02 | 1.826 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.491590e-02 | 1.826 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 1.491590e-02 | 1.826 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 1.491590e-02 | 1.826 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 1.391414e-02 | 1.857 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 1.411029e-02 | 1.850 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.491590e-02 | 1.826 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.429041e-02 | 1.845 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 1.336514e-02 | 1.874 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.389575e-02 | 1.857 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 1.492624e-02 | 1.826 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 1.535116e-02 | 1.814 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.539383e-02 | 1.813 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 1.606889e-02 | 1.794 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 1.614798e-02 | 1.792 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 1.634826e-02 | 1.787 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 1.638090e-02 | 1.786 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.665116e-02 | 1.779 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 1.665448e-02 | 1.778 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 1.665448e-02 | 1.778 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 1.678849e-02 | 1.775 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.681541e-02 | 1.774 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 1.681541e-02 | 1.774 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.681541e-02 | 1.774 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 1.681541e-02 | 1.774 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 1.681541e-02 | 1.774 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.681541e-02 | 1.774 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.681541e-02 | 1.774 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.681541e-02 | 1.774 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.681541e-02 | 1.774 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.681541e-02 | 1.774 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.681541e-02 | 1.774 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.681541e-02 | 1.774 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.681541e-02 | 1.774 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.681541e-02 | 1.774 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 1.681541e-02 | 1.774 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 1.697768e-02 | 1.770 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 1.697768e-02 | 1.770 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 1.700676e-02 | 1.769 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 2.064629e-02 | 1.685 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 1.919655e-02 | 1.717 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 1.919655e-02 | 1.717 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 1.952126e-02 | 1.709 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 1.814521e-02 | 1.741 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 2.064629e-02 | 1.685 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 1.849165e-02 | 1.733 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 2.074613e-02 | 1.683 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 2.165938e-02 | 1.664 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 2.172454e-02 | 1.663 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 2.178425e-02 | 1.662 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 2.182114e-02 | 1.661 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 2.182114e-02 | 1.661 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 2.182114e-02 | 1.661 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 2.182114e-02 | 1.661 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 2.200394e-02 | 1.657 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 2.293345e-02 | 1.640 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 2.293487e-02 | 1.640 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 2.316907e-02 | 1.635 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 2.316907e-02 | 1.635 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 2.346182e-02 | 1.630 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 2.395345e-02 | 1.621 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 2.437257e-02 | 1.613 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 2.480660e-02 | 1.605 | 1 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 2.553059e-02 | 1.593 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 2.575869e-02 | 1.589 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 2.624089e-02 | 1.581 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 2.636121e-02 | 1.579 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 2.636121e-02 | 1.579 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 2.677839e-02 | 1.572 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 2.721730e-02 | 1.565 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 2.734161e-02 | 1.563 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 2.756343e-02 | 1.560 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 2.814103e-02 | 1.551 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 2.822641e-02 | 1.549 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 2.930426e-02 | 1.533 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.966781e-02 | 1.528 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 2.976069e-02 | 1.526 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 3.026988e-02 | 1.519 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 3.026988e-02 | 1.519 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 3.549796e-02 | 1.450 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 3.549796e-02 | 1.450 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 3.549796e-02 | 1.450 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 3.228506e-02 | 1.491 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 3.228506e-02 | 1.491 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 3.228506e-02 | 1.491 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 3.228506e-02 | 1.491 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 3.755032e-02 | 1.425 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 3.148066e-02 | 1.502 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 3.830717e-02 | 1.417 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 3.830717e-02 | 1.417 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 3.228506e-02 | 1.491 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 3.416431e-02 | 1.466 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 3.184158e-02 | 1.497 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 3.148066e-02 | 1.502 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 3.570822e-02 | 1.447 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 3.352675e-02 | 1.475 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 3.699324e-02 | 1.432 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 3.148066e-02 | 1.502 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 3.833511e-02 | 1.416 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 3.833511e-02 | 1.416 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 3.833511e-02 | 1.416 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 4.024796e-02 | 1.395 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 4.024796e-02 | 1.395 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 4.044762e-02 | 1.393 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 4.057565e-02 | 1.392 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 4.067177e-02 | 1.391 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 4.311967e-02 | 1.365 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 4.313271e-02 | 1.365 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 4.456421e-02 | 1.351 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 4.456421e-02 | 1.351 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 4.456421e-02 | 1.351 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 4.469255e-02 | 1.350 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 4.479129e-02 | 1.349 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 4.479129e-02 | 1.349 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 4.491910e-02 | 1.348 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 4.491910e-02 | 1.348 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 4.503631e-02 | 1.346 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 4.503631e-02 | 1.346 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 4.503631e-02 | 1.346 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 4.510044e-02 | 1.346 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 4.510044e-02 | 1.346 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 4.681038e-02 | 1.330 | 0 | 0 |
| NFE2L2 regulating TCA cycle genes | R-HSA-9818025 | 4.681038e-02 | 1.330 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 4.681038e-02 | 1.330 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 4.681038e-02 | 1.330 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 4.775841e-02 | 1.321 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p14ARF Defects | R-HSA-9646303 | 4.775841e-02 | 1.321 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 4.775841e-02 | 1.321 | 0 | 0 |
| Deletions in the AXIN1 gene destabilize the destruction complex | R-HSA-5467345 | 4.775841e-02 | 1.321 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 4.775841e-02 | 1.321 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects | R-HSA-9646304 | 4.775841e-02 | 1.321 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 4.970425e-02 | 1.304 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 5.026510e-02 | 1.299 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 5.026510e-02 | 1.299 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 5.026510e-02 | 1.299 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 5.192058e-02 | 1.285 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 5.202465e-02 | 1.284 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 5.288689e-02 | 1.277 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 5.299559e-02 | 1.276 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 5.924212e-02 | 1.227 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 5.924212e-02 | 1.227 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 5.924212e-02 | 1.227 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 6.773862e-02 | 1.169 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 6.152303e-02 | 1.211 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 5.573001e-02 | 1.254 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 5.970355e-02 | 1.224 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 5.924212e-02 | 1.227 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 7.266077e-02 | 1.139 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 5.895662e-02 | 1.229 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 6.649516e-02 | 1.177 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 6.649516e-02 | 1.177 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 5.980676e-02 | 1.223 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 7.266077e-02 | 1.139 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 5.970355e-02 | 1.224 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 6.229159e-02 | 1.206 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 5.818539e-02 | 1.235 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 6.888481e-02 | 1.162 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 6.152303e-02 | 1.211 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 6.666596e-02 | 1.176 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 6.380566e-02 | 1.195 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 5.857816e-02 | 1.232 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 5.753557e-02 | 1.240 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 5.753557e-02 | 1.240 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 5.924212e-02 | 1.227 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 6.773862e-02 | 1.169 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 6.773862e-02 | 1.169 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 6.773862e-02 | 1.169 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 5.963684e-02 | 1.224 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 7.399586e-02 | 1.131 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 7.465365e-02 | 1.127 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 7.499888e-02 | 1.125 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 7.499888e-02 | 1.125 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 7.631116e-02 | 1.117 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 7.660205e-02 | 1.116 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 7.783430e-02 | 1.109 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 8.067565e-02 | 1.093 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 8.067565e-02 | 1.093 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 8.067565e-02 | 1.093 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 8.203480e-02 | 1.086 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 8.301712e-02 | 1.081 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 8.694396e-02 | 1.061 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 8.694396e-02 | 1.061 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 8.694396e-02 | 1.061 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 8.694396e-02 | 1.061 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 8.694396e-02 | 1.061 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 8.764286e-02 | 1.057 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 8.926891e-02 | 1.049 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 8.936335e-02 | 1.049 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 8.936335e-02 | 1.049 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 8.936335e-02 | 1.049 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function | R-HSA-9645722 | 9.323870e-02 | 1.030 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 9.323870e-02 | 1.030 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 9.323870e-02 | 1.030 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 9.323870e-02 | 1.030 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9632697 | 9.323870e-02 | 1.030 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 9.323870e-02 | 1.030 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9630791 | 9.323870e-02 | 1.030 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 1.365494e-01 | 0.865 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 1.365494e-01 | 0.865 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 1.365494e-01 | 0.865 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 1.365494e-01 | 0.865 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 1.365494e-01 | 0.865 | 0 | 0 |
| Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome | R-HSA-5678420 | 1.365494e-01 | 0.865 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 1.365494e-01 | 0.865 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 1.365494e-01 | 0.865 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 1.365494e-01 | 0.865 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 1.019787e-01 | 0.991 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.019787e-01 | 0.991 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 1.019787e-01 | 0.991 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.019787e-01 | 0.991 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 1.019787e-01 | 0.991 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 1.176610e-01 | 0.929 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 1.176610e-01 | 0.929 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 1.338947e-01 | 0.873 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 1.148864e-01 | 0.940 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 1.254880e-01 | 0.901 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 1.254880e-01 | 0.901 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 1.254880e-01 | 0.901 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 1.254880e-01 | 0.901 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 1.254880e-01 | 0.901 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 1.182350e-01 | 0.927 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 1.265210e-01 | 0.898 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.350433e-01 | 0.870 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 1.350433e-01 | 0.870 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 9.489041e-02 | 1.023 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 1.265210e-01 | 0.898 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.338947e-01 | 0.873 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 1.364255e-01 | 0.865 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 1.354864e-01 | 0.868 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 1.148864e-01 | 0.940 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 1.338947e-01 | 0.873 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.213395e-01 | 0.916 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 1.097944e-01 | 0.959 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 1.176610e-01 | 0.929 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 1.364255e-01 | 0.865 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 1.145393e-01 | 0.941 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 1.145393e-01 | 0.941 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 1.200319e-01 | 0.921 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 1.346891e-01 | 0.871 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 9.323870e-02 | 1.030 | 1 | 1 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 1.365494e-01 | 0.865 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 1.365494e-01 | 0.865 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 1.019787e-01 | 0.991 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 1.019787e-01 | 0.991 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 1.176610e-01 | 0.929 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 1.176610e-01 | 0.929 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 1.156167e-01 | 0.937 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 1.274159e-01 | 0.895 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 1.176610e-01 | 0.929 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 9.669846e-02 | 1.015 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 1.338947e-01 | 0.873 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 9.528874e-02 | 1.021 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.156497e-01 | 0.937 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 1.249661e-01 | 0.903 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 1.322535e-01 | 0.879 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 9.138564e-02 | 1.039 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 1.024185e-01 | 0.990 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 1.365494e-01 | 0.865 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 1.176610e-01 | 0.929 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 1.350433e-01 | 0.870 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 1.200319e-01 | 0.921 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 1.260703e-01 | 0.899 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 1.246472e-01 | 0.904 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 1.019787e-01 | 0.991 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 1.338947e-01 | 0.873 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 9.210620e-02 | 1.036 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 9.198290e-02 | 1.036 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 1.019787e-01 | 0.991 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 1.114658e-01 | 0.953 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 9.489041e-02 | 1.023 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 1.019787e-01 | 0.991 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 1.019787e-01 | 0.991 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 1.265210e-01 | 0.898 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 1.322535e-01 | 0.879 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 1.000770e-01 | 1.000 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 1.385783e-01 | 0.858 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 1.437540e-01 | 0.842 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 1.437918e-01 | 0.842 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 1.437918e-01 | 0.842 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 1.437918e-01 | 0.842 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 1.437918e-01 | 0.842 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 1.441211e-01 | 0.841 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 1.444039e-01 | 0.840 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 1.456627e-01 | 0.837 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 1.476748e-01 | 0.831 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 1.488969e-01 | 0.827 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 1.488969e-01 | 0.827 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 1.505916e-01 | 0.822 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 1.505916e-01 | 0.822 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 1.505916e-01 | 0.822 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 1.514346e-01 | 0.820 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 1.535850e-01 | 0.814 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 1.573724e-01 | 0.803 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 1.584884e-01 | 0.800 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 1.584884e-01 | 0.800 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 1.588241e-01 | 0.799 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 1.590666e-01 | 0.798 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 1.590666e-01 | 0.798 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 1.590666e-01 | 0.798 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 1.592118e-01 | 0.798 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 1.592118e-01 | 0.798 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 1.619255e-01 | 0.791 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 1.619255e-01 | 0.791 | 0 | 0 |
| Defective PAPSS2 causes SEMD-PA | R-HSA-3560796 | 1.777939e-01 | 0.750 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 1.777939e-01 | 0.750 | 0 | 0 |
| Potassium transport channels | R-HSA-1296067 | 1.777939e-01 | 0.750 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 1.777939e-01 | 0.750 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 2.170707e-01 | 0.663 | 0 | 0 |
| Classical Kir channels | R-HSA-1296053 | 2.170707e-01 | 0.663 | 0 | 0 |
| Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine | R-HSA-9735763 | 2.544735e-01 | 0.594 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 2.544735e-01 | 0.594 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 2.544735e-01 | 0.594 | 0 | 0 |
| Nucleotide catabolism defects | R-HSA-9735786 | 2.544735e-01 | 0.594 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 2.544735e-01 | 0.594 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 2.544735e-01 | 0.594 | 0 | 0 |
| Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate | R-HSA-2978092 | 2.544735e-01 | 0.594 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 2.544735e-01 | 0.594 | 0 | 0 |
| IRS activation | R-HSA-74713 | 2.900916e-01 | 0.537 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 2.900916e-01 | 0.537 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 2.900916e-01 | 0.537 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 2.900916e-01 | 0.537 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 2.900916e-01 | 0.537 | 0 | 0 |
| Plus-strand DNA synthesis | R-HSA-164525 | 3.240101e-01 | 0.489 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 3.240101e-01 | 0.489 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 3.240101e-01 | 0.489 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 3.240101e-01 | 0.489 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 2.026835e-01 | 0.693 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 2.204866e-01 | 0.657 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 2.564008e-01 | 0.591 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 2.564008e-01 | 0.591 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 1.953109e-01 | 0.709 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 1.712890e-01 | 0.766 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 2.924022e-01 | 0.534 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.905541e-01 | 0.720 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 3.103305e-01 | 0.508 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 2.460566e-01 | 0.609 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 2.004333e-01 | 0.698 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 1.819058e-01 | 0.740 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 2.721590e-01 | 0.565 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.938510e-01 | 0.713 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 2.731400e-01 | 0.564 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 2.219214e-01 | 0.654 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 2.478838e-01 | 0.606 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 2.289664e-01 | 0.640 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 2.974502e-01 | 0.527 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 2.380509e-01 | 0.623 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 2.578628e-01 | 0.589 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 2.652487e-01 | 0.576 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 2.332529e-01 | 0.632 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 1.750081e-01 | 0.757 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.916677e-01 | 0.717 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 1.953109e-01 | 0.709 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 3.068709e-01 | 0.513 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 3.103305e-01 | 0.508 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 2.207069e-01 | 0.656 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 2.853222e-01 | 0.545 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 2.726923e-01 | 0.564 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 3.103305e-01 | 0.508 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 2.026835e-01 | 0.693 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 2.012703e-01 | 0.696 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 2.953339e-01 | 0.530 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 2.564008e-01 | 0.591 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 2.564008e-01 | 0.591 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 3.250401e-01 | 0.488 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 2.603236e-01 | 0.584 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 3.067385e-01 | 0.513 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 1.905541e-01 | 0.720 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 3.067385e-01 | 0.513 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 2.544735e-01 | 0.594 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 2.384097e-01 | 0.623 | 0 | 0 |
| PKA activation | R-HSA-163615 | 3.103305e-01 | 0.508 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 2.012852e-01 | 0.696 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 2.564008e-01 | 0.591 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 2.787622e-01 | 0.555 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 1.819058e-01 | 0.740 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 2.853222e-01 | 0.545 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 1.905541e-01 | 0.720 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 3.117801e-01 | 0.506 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 2.070520e-01 | 0.684 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 2.900916e-01 | 0.537 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 2.026835e-01 | 0.693 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 2.384097e-01 | 0.623 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 2.309216e-01 | 0.637 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 2.985351e-01 | 0.525 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 2.985351e-01 | 0.525 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 2.380509e-01 | 0.623 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 2.959588e-01 | 0.529 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 2.731400e-01 | 0.564 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 3.117801e-01 | 0.506 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 2.026835e-01 | 0.693 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 2.726923e-01 | 0.564 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 2.156776e-01 | 0.666 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 2.544735e-01 | 0.594 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 2.544735e-01 | 0.594 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 2.900916e-01 | 0.537 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 3.240101e-01 | 0.489 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 2.384097e-01 | 0.623 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 2.652487e-01 | 0.576 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 2.088220e-01 | 0.680 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 2.695083e-01 | 0.569 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 2.590640e-01 | 0.587 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 1.850573e-01 | 0.733 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 2.590640e-01 | 0.587 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 2.744126e-01 | 0.562 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 1.905541e-01 | 0.720 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 1.777939e-01 | 0.750 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 1.777939e-01 | 0.750 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 2.170707e-01 | 0.663 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 2.544735e-01 | 0.594 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 2.544735e-01 | 0.594 | 0 | 0 |
| ATP sensitive Potassium channels | R-HSA-1296025 | 2.544735e-01 | 0.594 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 2.900916e-01 | 0.537 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 2.900916e-01 | 0.537 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 1.676707e-01 | 0.776 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 3.240101e-01 | 0.489 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 3.240101e-01 | 0.489 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 3.240101e-01 | 0.489 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 2.564008e-01 | 0.591 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 2.203847e-01 | 0.657 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 2.331566e-01 | 0.632 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 2.004333e-01 | 0.698 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 2.004333e-01 | 0.698 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.658166e-01 | 0.780 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 1.865237e-01 | 0.729 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 1.938510e-01 | 0.713 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 1.938510e-01 | 0.713 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 3.250401e-01 | 0.488 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 2.512149e-01 | 0.600 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 2.859008e-01 | 0.544 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 2.257412e-01 | 0.646 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 2.990311e-01 | 0.524 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 2.360864e-01 | 0.627 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 2.731400e-01 | 0.564 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 2.325350e-01 | 0.634 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 1.955323e-01 | 0.709 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 2.012852e-01 | 0.696 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 2.544735e-01 | 0.594 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.756256e-01 | 0.755 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 3.112076e-01 | 0.507 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 1.947169e-01 | 0.711 | 1 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 2.506922e-01 | 0.601 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 1.641105e-01 | 0.785 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 2.204866e-01 | 0.657 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 2.204866e-01 | 0.657 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 2.564008e-01 | 0.591 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 2.295004e-01 | 0.639 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 1.905493e-01 | 0.720 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 2.700244e-01 | 0.569 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 2.624506e-01 | 0.581 | 0 | 0 |
| Intracellular oxygen transport | R-HSA-8981607 | 2.170707e-01 | 0.663 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 2.170707e-01 | 0.663 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 2.170707e-01 | 0.663 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 2.544735e-01 | 0.594 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 2.900916e-01 | 0.537 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 3.240101e-01 | 0.489 | 0 | 0 |
| VEGF binds to VEGFR leading to receptor dimerization | R-HSA-195399 | 3.240101e-01 | 0.489 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 3.240101e-01 | 0.489 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 2.026835e-01 | 0.693 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 2.331566e-01 | 0.632 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 3.103305e-01 | 0.508 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 3.240101e-01 | 0.489 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 2.206283e-01 | 0.656 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 1.749848e-01 | 0.757 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 3.055982e-01 | 0.515 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 2.829092e-01 | 0.548 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 1.953109e-01 | 0.709 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 2.170707e-01 | 0.663 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 2.206283e-01 | 0.656 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 1.865237e-01 | 0.729 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 3.106518e-01 | 0.508 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 3.250401e-01 | 0.488 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 3.103305e-01 | 0.508 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 2.384097e-01 | 0.623 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 2.924022e-01 | 0.534 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 2.731400e-01 | 0.564 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 2.947242e-01 | 0.531 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 1.777939e-01 | 0.750 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 2.170707e-01 | 0.663 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 2.900916e-01 | 0.537 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 2.900916e-01 | 0.537 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 1.850573e-01 | 0.733 | 0 | 0 |
| VEGF ligand-receptor interactions | R-HSA-194313 | 3.240101e-01 | 0.489 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 1.710126e-01 | 0.767 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 2.722550e-01 | 0.565 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 1.973090e-01 | 0.705 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 1.938510e-01 | 0.713 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 1.746936e-01 | 0.758 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 2.590640e-01 | 0.587 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 1.866630e-01 | 0.729 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 1.850573e-01 | 0.733 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 1.953109e-01 | 0.709 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 2.331566e-01 | 0.632 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 2.787622e-01 | 0.555 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 3.103305e-01 | 0.508 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 3.163339e-01 | 0.500 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 2.900916e-01 | 0.537 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 1.676707e-01 | 0.776 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 3.240101e-01 | 0.489 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 2.384097e-01 | 0.623 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 2.744126e-01 | 0.562 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 3.231881e-01 | 0.491 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 2.518438e-01 | 0.599 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 3.240101e-01 | 0.489 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 3.240101e-01 | 0.489 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 3.240101e-01 | 0.489 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 2.985351e-01 | 0.525 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 2.077622e-01 | 0.682 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 2.026835e-01 | 0.693 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 2.900916e-01 | 0.537 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 3.240101e-01 | 0.489 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 1.905541e-01 | 0.720 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 3.103305e-01 | 0.508 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 2.026835e-01 | 0.693 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 2.924022e-01 | 0.534 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 2.026835e-01 | 0.693 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 2.104618e-01 | 0.677 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 2.924022e-01 | 0.534 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 3.103305e-01 | 0.508 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 2.204866e-01 | 0.657 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 3.225001e-01 | 0.491 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 2.077622e-01 | 0.682 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 2.203847e-01 | 0.657 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 1.830534e-01 | 0.737 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 3.258328e-01 | 0.487 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 3.261153e-01 | 0.487 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 3.281625e-01 | 0.484 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 3.281625e-01 | 0.484 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 3.281625e-01 | 0.484 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 3.281625e-01 | 0.484 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 3.287713e-01 | 0.483 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 3.338930e-01 | 0.476 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 3.344919e-01 | 0.476 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 3.353611e-01 | 0.474 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 3.359177e-01 | 0.474 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 3.382990e-01 | 0.471 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 3.384279e-01 | 0.471 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 3.413577e-01 | 0.467 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 3.413577e-01 | 0.467 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 3.416965e-01 | 0.466 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 3.416965e-01 | 0.466 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 3.458665e-01 | 0.461 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 3.458665e-01 | 0.461 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 3.458665e-01 | 0.461 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 3.494085e-01 | 0.457 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 3.515412e-01 | 0.454 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 3.533292e-01 | 0.452 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 3.562414e-01 | 0.448 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 3.563099e-01 | 0.448 | 0 | 0 |
| Uncoating of the HIV Virion | R-HSA-162585 | 3.563099e-01 | 0.448 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 3.563099e-01 | 0.448 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 3.563099e-01 | 0.448 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 3.563099e-01 | 0.448 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 3.563099e-01 | 0.448 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 3.563099e-01 | 0.448 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 3.563099e-01 | 0.448 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 3.603925e-01 | 0.443 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 3.603925e-01 | 0.443 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 3.634141e-01 | 0.440 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 3.634141e-01 | 0.440 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 3.634141e-01 | 0.440 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 3.634141e-01 | 0.440 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 3.647522e-01 | 0.438 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 3.652281e-01 | 0.437 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 3.653001e-01 | 0.437 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 3.713712e-01 | 0.430 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 3.736439e-01 | 0.428 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 3.739070e-01 | 0.427 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 3.779181e-01 | 0.423 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 3.779181e-01 | 0.423 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 3.789833e-01 | 0.421 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 3.789833e-01 | 0.421 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 3.789833e-01 | 0.421 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 3.789833e-01 | 0.421 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 3.807799e-01 | 0.419 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 3.823360e-01 | 0.418 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 3.870683e-01 | 0.412 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 3.870683e-01 | 0.412 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 3.870683e-01 | 0.412 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 3.870683e-01 | 0.412 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 3.870683e-01 | 0.412 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 3.870683e-01 | 0.412 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 3.870683e-01 | 0.412 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 3.870683e-01 | 0.412 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 3.870683e-01 | 0.412 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 3.870683e-01 | 0.412 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 3.870683e-01 | 0.412 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 3.870683e-01 | 0.412 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 3.870683e-01 | 0.412 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 3.904161e-01 | 0.408 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 3.910256e-01 | 0.408 | 1 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 3.910256e-01 | 0.408 | 0 | 0 |
| Immune System | R-HSA-168256 | 3.915694e-01 | 0.407 | 1 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 3.932790e-01 | 0.405 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 3.979411e-01 | 0.400 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 3.979411e-01 | 0.400 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 3.979411e-01 | 0.400 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 3.997438e-01 | 0.398 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 4.001588e-01 | 0.398 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 4.040625e-01 | 0.394 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 4.040625e-01 | 0.394 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 4.040625e-01 | 0.394 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 4.041921e-01 | 0.393 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 4.083477e-01 | 0.389 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 4.148778e-01 | 0.382 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 4.148778e-01 | 0.382 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 4.148778e-01 | 0.382 | 0 | 0 |
| Reverse Transcription of HIV RNA | R-HSA-162589 | 4.163587e-01 | 0.381 | 0 | 0 |
| Minus-strand DNA synthesis | R-HSA-164516 | 4.163587e-01 | 0.381 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 4.163587e-01 | 0.381 | 0 | 0 |
| RSK activation | R-HSA-444257 | 4.163587e-01 | 0.381 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 4.163587e-01 | 0.381 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 4.163587e-01 | 0.381 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 4.163587e-01 | 0.381 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 4.163587e-01 | 0.381 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 4.163587e-01 | 0.381 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 4.163587e-01 | 0.381 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 4.163587e-01 | 0.381 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 4.163587e-01 | 0.381 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 4.170171e-01 | 0.380 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 4.199605e-01 | 0.377 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 4.284126e-01 | 0.368 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 4.298784e-01 | 0.367 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 4.309370e-01 | 0.366 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 4.315721e-01 | 0.365 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 4.315721e-01 | 0.365 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 4.315721e-01 | 0.365 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 4.315721e-01 | 0.365 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 4.366785e-01 | 0.360 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 4.374023e-01 | 0.359 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 4.426363e-01 | 0.354 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 4.442511e-01 | 0.352 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 4.442511e-01 | 0.352 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 4.442511e-01 | 0.352 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 4.442511e-01 | 0.352 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 4.442511e-01 | 0.352 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 4.442511e-01 | 0.352 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 4.442511e-01 | 0.352 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 4.442511e-01 | 0.352 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 4.442511e-01 | 0.352 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 4.442511e-01 | 0.352 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 4.442511e-01 | 0.352 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 4.442511e-01 | 0.352 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 4.473999e-01 | 0.349 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 4.473999e-01 | 0.349 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 4.480088e-01 | 0.349 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 4.480088e-01 | 0.349 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 4.480088e-01 | 0.349 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 4.504936e-01 | 0.346 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 4.552811e-01 | 0.342 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 4.552811e-01 | 0.342 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 4.552811e-01 | 0.342 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 4.580566e-01 | 0.339 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 4.580566e-01 | 0.339 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 4.580566e-01 | 0.339 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 4.589341e-01 | 0.338 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 4.595983e-01 | 0.338 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 4.641742e-01 | 0.333 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 4.641742e-01 | 0.333 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 4.641742e-01 | 0.333 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 4.641742e-01 | 0.333 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 4.641742e-01 | 0.333 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 4.657387e-01 | 0.332 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 4.680613e-01 | 0.330 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 4.708121e-01 | 0.327 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 4.708121e-01 | 0.327 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 4.708121e-01 | 0.327 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 4.708121e-01 | 0.327 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 4.708121e-01 | 0.327 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 4.708121e-01 | 0.327 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 4.708121e-01 | 0.327 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 4.708121e-01 | 0.327 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 4.708121e-01 | 0.327 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 4.708121e-01 | 0.327 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 4.725271e-01 | 0.326 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 4.725271e-01 | 0.326 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 4.777025e-01 | 0.321 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 4.778406e-01 | 0.321 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 4.778406e-01 | 0.321 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 4.800567e-01 | 0.319 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 4.800567e-01 | 0.319 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 4.800567e-01 | 0.319 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 4.800567e-01 | 0.319 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 4.800567e-01 | 0.319 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 4.800567e-01 | 0.319 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 4.800567e-01 | 0.319 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 4.801970e-01 | 0.319 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 4.801970e-01 | 0.319 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 4.801970e-01 | 0.319 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 4.860480e-01 | 0.313 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 4.881759e-01 | 0.311 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 4.895807e-01 | 0.310 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 4.905303e-01 | 0.309 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 4.905303e-01 | 0.309 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 4.905303e-01 | 0.309 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 4.924522e-01 | 0.308 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 4.924522e-01 | 0.308 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 4.931835e-01 | 0.307 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 4.939520e-01 | 0.306 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 4.946692e-01 | 0.306 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 4.953224e-01 | 0.305 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 4.956465e-01 | 0.305 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 4.956465e-01 | 0.305 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 4.956465e-01 | 0.305 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 4.956465e-01 | 0.305 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 4.956465e-01 | 0.305 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 4.956465e-01 | 0.305 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 4.956465e-01 | 0.305 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 4.961052e-01 | 0.304 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 4.961052e-01 | 0.304 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 4.961052e-01 | 0.304 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 4.961052e-01 | 0.304 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 4.961052e-01 | 0.304 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 4.961052e-01 | 0.304 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 4.961052e-01 | 0.304 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 4.961052e-01 | 0.304 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 4.961052e-01 | 0.304 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 4.961052e-01 | 0.304 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 4.961052e-01 | 0.304 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 5.031723e-01 | 0.298 | 1 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 5.068135e-01 | 0.295 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 5.101712e-01 | 0.292 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 5.109354e-01 | 0.292 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 5.109354e-01 | 0.292 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 5.109354e-01 | 0.292 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 5.122320e-01 | 0.291 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 5.144097e-01 | 0.289 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 5.165223e-01 | 0.287 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 5.178999e-01 | 0.286 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 5.184882e-01 | 0.285 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 5.201908e-01 | 0.284 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 5.201908e-01 | 0.284 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 5.201908e-01 | 0.284 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 5.201908e-01 | 0.284 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 5.201908e-01 | 0.284 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 5.201908e-01 | 0.284 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 5.201908e-01 | 0.284 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 5.201908e-01 | 0.284 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 5.201908e-01 | 0.284 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 5.201908e-01 | 0.284 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 5.201908e-01 | 0.284 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 5.259163e-01 | 0.279 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 5.259163e-01 | 0.279 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 5.259163e-01 | 0.279 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 5.259163e-01 | 0.279 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 5.399655e-01 | 0.268 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 5.403246e-01 | 0.267 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 5.405840e-01 | 0.267 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 5.405840e-01 | 0.267 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 5.405840e-01 | 0.267 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 5.405840e-01 | 0.267 | 1 | 1 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 5.431266e-01 | 0.265 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 5.431266e-01 | 0.265 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 5.431266e-01 | 0.265 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 5.431266e-01 | 0.265 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 5.431266e-01 | 0.265 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 5.431266e-01 | 0.265 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 5.431266e-01 | 0.265 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 5.431266e-01 | 0.265 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 5.431266e-01 | 0.265 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 5.431266e-01 | 0.265 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 5.431266e-01 | 0.265 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 5.431266e-01 | 0.265 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 5.431266e-01 | 0.265 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 5.431266e-01 | 0.265 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 5.432584e-01 | 0.265 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 5.514392e-01 | 0.259 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 5.514392e-01 | 0.259 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 5.549340e-01 | 0.256 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 5.585446e-01 | 0.253 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 5.598918e-01 | 0.252 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 5.627418e-01 | 0.250 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 5.649673e-01 | 0.248 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 5.649673e-01 | 0.248 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 5.649673e-01 | 0.248 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 5.649673e-01 | 0.248 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 5.649673e-01 | 0.248 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 5.649673e-01 | 0.248 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 5.649673e-01 | 0.248 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 5.649673e-01 | 0.248 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 5.649673e-01 | 0.248 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 5.649673e-01 | 0.248 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 5.649673e-01 | 0.248 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 5.649673e-01 | 0.248 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 5.649673e-01 | 0.248 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 5.649673e-01 | 0.248 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 5.649673e-01 | 0.248 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 5.689633e-01 | 0.245 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 5.689633e-01 | 0.245 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 5.689633e-01 | 0.245 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 5.689633e-01 | 0.245 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 5.689633e-01 | 0.245 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 5.689633e-01 | 0.245 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 5.689633e-01 | 0.245 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 5.695045e-01 | 0.245 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 5.695045e-01 | 0.245 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 5.695045e-01 | 0.245 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 5.716326e-01 | 0.243 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 5.735906e-01 | 0.241 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 5.738694e-01 | 0.241 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 5.789992e-01 | 0.237 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 5.789992e-01 | 0.237 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 5.789992e-01 | 0.237 | 1 | 1 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 5.812864e-01 | 0.236 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 5.826697e-01 | 0.235 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 5.826697e-01 | 0.235 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 5.826697e-01 | 0.235 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 5.848189e-01 | 0.233 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 5.857652e-01 | 0.232 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 5.857652e-01 | 0.232 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 5.857652e-01 | 0.232 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 5.857652e-01 | 0.232 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 5.857652e-01 | 0.232 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 5.857652e-01 | 0.232 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 5.857652e-01 | 0.232 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 5.857652e-01 | 0.232 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 5.857652e-01 | 0.232 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 5.857652e-01 | 0.232 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 5.857652e-01 | 0.232 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 5.883732e-01 | 0.230 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 5.915401e-01 | 0.228 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 5.923631e-01 | 0.227 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 5.935873e-01 | 0.227 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 5.955872e-01 | 0.225 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 5.960520e-01 | 0.225 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 5.960520e-01 | 0.225 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 5.960520e-01 | 0.225 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 5.960520e-01 | 0.225 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 6.055700e-01 | 0.218 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 6.055700e-01 | 0.218 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 6.055700e-01 | 0.218 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 6.055700e-01 | 0.218 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 6.055700e-01 | 0.218 | 0 | 0 |
| Transport and metabolism of PAPS | R-HSA-174362 | 6.055700e-01 | 0.218 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 6.055700e-01 | 0.218 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 6.055700e-01 | 0.218 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 6.061720e-01 | 0.217 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 6.061720e-01 | 0.217 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 6.087244e-01 | 0.216 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 6.087244e-01 | 0.216 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 6.091099e-01 | 0.215 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 6.157475e-01 | 0.211 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 6.167614e-01 | 0.210 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 6.218438e-01 | 0.206 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 6.218438e-01 | 0.206 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 6.218438e-01 | 0.206 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 6.218438e-01 | 0.206 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 6.244291e-01 | 0.205 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 6.244291e-01 | 0.205 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 6.244291e-01 | 0.205 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 6.244291e-01 | 0.205 | 0 | 0 |
| Activation of the phototransduction cascade | R-HSA-2485179 | 6.244291e-01 | 0.205 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 6.244291e-01 | 0.205 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 6.244291e-01 | 0.205 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 6.244291e-01 | 0.205 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 6.244291e-01 | 0.205 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 6.244291e-01 | 0.205 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 6.244291e-01 | 0.205 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 6.244291e-01 | 0.205 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 6.244291e-01 | 0.205 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 6.244291e-01 | 0.205 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 6.267831e-01 | 0.203 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 6.267831e-01 | 0.203 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 6.277500e-01 | 0.202 | 1 | 0 |
| Glycolysis | R-HSA-70171 | 6.325402e-01 | 0.199 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 6.333542e-01 | 0.198 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 6.342548e-01 | 0.198 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 6.342548e-01 | 0.198 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 6.361539e-01 | 0.196 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 6.368064e-01 | 0.196 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 6.368064e-01 | 0.196 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 6.368064e-01 | 0.196 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 6.368064e-01 | 0.196 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 6.368064e-01 | 0.196 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 6.368064e-01 | 0.196 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 6.423019e-01 | 0.192 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 6.423875e-01 | 0.192 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 6.423875e-01 | 0.192 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 6.423875e-01 | 0.192 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 6.423875e-01 | 0.192 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 6.423875e-01 | 0.192 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 6.423875e-01 | 0.192 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 6.423875e-01 | 0.192 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 6.423875e-01 | 0.192 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 6.423875e-01 | 0.192 | 0 | 0 |
| Depurination | R-HSA-73927 | 6.463447e-01 | 0.190 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 6.463447e-01 | 0.190 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 6.463447e-01 | 0.190 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 6.463447e-01 | 0.190 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 6.463447e-01 | 0.190 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 6.466400e-01 | 0.189 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 6.479164e-01 | 0.188 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 6.504322e-01 | 0.187 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 6.554396e-01 | 0.183 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 6.562834e-01 | 0.183 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 6.562834e-01 | 0.183 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 6.581158e-01 | 0.182 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 6.581158e-01 | 0.182 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 6.581158e-01 | 0.182 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 6.587700e-01 | 0.181 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 6.594883e-01 | 0.181 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 6.594883e-01 | 0.181 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 6.594883e-01 | 0.181 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 6.594883e-01 | 0.181 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 6.594883e-01 | 0.181 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 6.594883e-01 | 0.181 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 6.594883e-01 | 0.181 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 6.594883e-01 | 0.181 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 6.594883e-01 | 0.181 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 6.665365e-01 | 0.176 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 6.665365e-01 | 0.176 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 6.676758e-01 | 0.175 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 6.685520e-01 | 0.175 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 6.695710e-01 | 0.174 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 6.695710e-01 | 0.174 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 6.695710e-01 | 0.174 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 6.695710e-01 | 0.174 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 6.695710e-01 | 0.174 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 6.695710e-01 | 0.174 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 6.695710e-01 | 0.174 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 6.695710e-01 | 0.174 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 6.695710e-01 | 0.174 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 6.695710e-01 | 0.174 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 6.695710e-01 | 0.174 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 6.695710e-01 | 0.174 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 6.757723e-01 | 0.170 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 6.757723e-01 | 0.170 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 6.757723e-01 | 0.170 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 6.757723e-01 | 0.170 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 6.757723e-01 | 0.170 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 6.757723e-01 | 0.170 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 6.757723e-01 | 0.170 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 6.757723e-01 | 0.170 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 6.757723e-01 | 0.170 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 6.807135e-01 | 0.167 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 6.807135e-01 | 0.167 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 6.807135e-01 | 0.167 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 6.807135e-01 | 0.167 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 6.807135e-01 | 0.167 | 0 | 0 |
| Disease | R-HSA-1643685 | 6.821162e-01 | 0.166 | 1 | 0 |
| Infectious disease | R-HSA-5663205 | 6.853410e-01 | 0.164 | 1 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 6.912785e-01 | 0.160 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 6.912785e-01 | 0.160 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 6.912785e-01 | 0.160 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 6.912785e-01 | 0.160 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 6.912785e-01 | 0.160 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 6.915470e-01 | 0.160 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 6.915470e-01 | 0.160 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 6.915470e-01 | 0.160 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 6.915470e-01 | 0.160 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 6.915470e-01 | 0.160 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 6.915470e-01 | 0.160 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 6.915470e-01 | 0.160 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 6.915470e-01 | 0.160 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 6.929503e-01 | 0.159 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 6.938193e-01 | 0.159 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 6.973670e-01 | 0.157 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 6.984498e-01 | 0.156 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 7.020756e-01 | 0.154 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 7.020756e-01 | 0.154 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 7.020756e-01 | 0.154 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 7.020756e-01 | 0.154 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 7.020756e-01 | 0.154 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 7.020756e-01 | 0.154 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 7.020756e-01 | 0.154 | 0 | 0 |
| S Phase | R-HSA-69242 | 7.027435e-01 | 0.153 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 7.059391e-01 | 0.151 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 7.060440e-01 | 0.151 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 7.060440e-01 | 0.151 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 7.060440e-01 | 0.151 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 7.060440e-01 | 0.151 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 7.060440e-01 | 0.151 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 7.060440e-01 | 0.151 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 7.060440e-01 | 0.151 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 7.060440e-01 | 0.151 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 7.101448e-01 | 0.149 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 7.121194e-01 | 0.147 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 7.123036e-01 | 0.147 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 7.133217e-01 | 0.147 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 7.142189e-01 | 0.146 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 7.184601e-01 | 0.144 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 7.201042e-01 | 0.143 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 7.201042e-01 | 0.143 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 7.201042e-01 | 0.143 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 7.201042e-01 | 0.143 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 7.201042e-01 | 0.143 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 7.201042e-01 | 0.143 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 7.201042e-01 | 0.143 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 7.205667e-01 | 0.142 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 7.222358e-01 | 0.141 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 7.249798e-01 | 0.140 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 7.304010e-01 | 0.136 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 7.318770e-01 | 0.136 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 7.318770e-01 | 0.136 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 7.318770e-01 | 0.136 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 7.318770e-01 | 0.136 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 7.318770e-01 | 0.136 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 7.318770e-01 | 0.136 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 7.334926e-01 | 0.135 | 0 | 0 |
| Eicosanoids | R-HSA-211979 | 7.334926e-01 | 0.135 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 7.334926e-01 | 0.135 | 0 | 0 |
| Miscellaneous substrates | R-HSA-211958 | 7.334926e-01 | 0.135 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 7.334926e-01 | 0.135 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 7.334926e-01 | 0.135 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 7.376110e-01 | 0.132 | 1 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 7.412323e-01 | 0.130 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 7.412323e-01 | 0.130 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 7.412323e-01 | 0.130 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 7.414899e-01 | 0.130 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 7.422940e-01 | 0.129 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 7.462415e-01 | 0.127 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 7.462415e-01 | 0.127 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 7.462415e-01 | 0.127 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 7.462415e-01 | 0.127 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 7.462415e-01 | 0.127 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 7.462415e-01 | 0.127 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 7.520042e-01 | 0.124 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 7.556235e-01 | 0.122 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 7.570992e-01 | 0.121 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 7.583812e-01 | 0.120 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 7.583812e-01 | 0.120 | 0 | 0 |
| Fatty acids | R-HSA-211935 | 7.583812e-01 | 0.120 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 7.583812e-01 | 0.120 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 7.584480e-01 | 0.120 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 7.591064e-01 | 0.120 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 7.671596e-01 | 0.115 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 7.672837e-01 | 0.115 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 7.676362e-01 | 0.115 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 7.676362e-01 | 0.115 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 7.676362e-01 | 0.115 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 7.699408e-01 | 0.114 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 7.699408e-01 | 0.114 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 7.699408e-01 | 0.114 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 7.699408e-01 | 0.114 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 7.699408e-01 | 0.114 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 7.699408e-01 | 0.114 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 7.699408e-01 | 0.114 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 7.759021e-01 | 0.110 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 7.784142e-01 | 0.109 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 7.784195e-01 | 0.109 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 7.809481e-01 | 0.107 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 7.809481e-01 | 0.107 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 7.809481e-01 | 0.107 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 7.809481e-01 | 0.107 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 7.809481e-01 | 0.107 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 7.809481e-01 | 0.107 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 7.809481e-01 | 0.107 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 7.809481e-01 | 0.107 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 7.809481e-01 | 0.107 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 7.809481e-01 | 0.107 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 7.839096e-01 | 0.106 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 7.851163e-01 | 0.105 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 7.851163e-01 | 0.105 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 7.914293e-01 | 0.102 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 7.914293e-01 | 0.102 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 7.914293e-01 | 0.102 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 7.914293e-01 | 0.102 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 7.914293e-01 | 0.102 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 7.916498e-01 | 0.101 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 7.916498e-01 | 0.101 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 7.916498e-01 | 0.101 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 7.916647e-01 | 0.101 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 7.916647e-01 | 0.101 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 7.916647e-01 | 0.101 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 7.916647e-01 | 0.101 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 7.991731e-01 | 0.097 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 7.991731e-01 | 0.097 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 7.994546e-01 | 0.097 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 8.014097e-01 | 0.096 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 8.014097e-01 | 0.096 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 8.014097e-01 | 0.096 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 8.042210e-01 | 0.095 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 8.109130e-01 | 0.091 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 8.109130e-01 | 0.091 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 8.134732e-01 | 0.090 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 8.188853e-01 | 0.087 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 8.199622e-01 | 0.086 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 8.199622e-01 | 0.086 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 8.202766e-01 | 0.086 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 8.218773e-01 | 0.085 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 8.235715e-01 | 0.084 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 8.268567e-01 | 0.083 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 8.274533e-01 | 0.082 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 8.285788e-01 | 0.082 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 8.285788e-01 | 0.082 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 8.285788e-01 | 0.082 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 8.285788e-01 | 0.082 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 8.332192e-01 | 0.079 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 8.367835e-01 | 0.077 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 8.367835e-01 | 0.077 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 8.367835e-01 | 0.077 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 8.393699e-01 | 0.076 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 8.393699e-01 | 0.076 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 8.410128e-01 | 0.075 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 8.416147e-01 | 0.075 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 8.445960e-01 | 0.073 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 8.445960e-01 | 0.073 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 8.453144e-01 | 0.073 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 8.453144e-01 | 0.073 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 8.453144e-01 | 0.073 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 8.453144e-01 | 0.073 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 8.453144e-01 | 0.073 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 8.453144e-01 | 0.073 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 8.471265e-01 | 0.072 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 8.510585e-01 | 0.070 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 8.510585e-01 | 0.070 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 8.520349e-01 | 0.070 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 8.520349e-01 | 0.070 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 8.566076e-01 | 0.067 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 8.566076e-01 | 0.067 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 8.566076e-01 | 0.067 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 8.591182e-01 | 0.066 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 8.591182e-01 | 0.066 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 8.624400e-01 | 0.064 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 8.640084e-01 | 0.063 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 8.658629e-01 | 0.063 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 8.658629e-01 | 0.063 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 8.658629e-01 | 0.063 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 8.658629e-01 | 0.063 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 8.658629e-01 | 0.063 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 8.658629e-01 | 0.063 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 8.672569e-01 | 0.062 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 8.718339e-01 | 0.060 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 8.722850e-01 | 0.059 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 8.722850e-01 | 0.059 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 8.754223e-01 | 0.058 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 8.755992e-01 | 0.058 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 8.763335e-01 | 0.057 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 8.769632e-01 | 0.057 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 8.784000e-01 | 0.056 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 8.784000e-01 | 0.056 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 8.784000e-01 | 0.056 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 8.784000e-01 | 0.056 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 8.784000e-01 | 0.056 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 8.816183e-01 | 0.055 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 8.828434e-01 | 0.054 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 8.842226e-01 | 0.053 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 8.842226e-01 | 0.053 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 8.842226e-01 | 0.053 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 8.842226e-01 | 0.053 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 8.842226e-01 | 0.053 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 8.863261e-01 | 0.052 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 8.897668e-01 | 0.051 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 8.897668e-01 | 0.051 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 8.897668e-01 | 0.051 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 8.897668e-01 | 0.051 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 8.950457e-01 | 0.048 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 9.000722e-01 | 0.046 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 9.000722e-01 | 0.046 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.000722e-01 | 0.046 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 9.000722e-01 | 0.046 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.000722e-01 | 0.046 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 9.025422e-01 | 0.045 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 9.025422e-01 | 0.045 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.025763e-01 | 0.045 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.048582e-01 | 0.043 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 9.048582e-01 | 0.043 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 9.048582e-01 | 0.043 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.048582e-01 | 0.043 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 9.051327e-01 | 0.043 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.053813e-01 | 0.043 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 9.094153e-01 | 0.041 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.094153e-01 | 0.041 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.099025e-01 | 0.041 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.133844e-01 | 0.039 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.133844e-01 | 0.039 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 9.167397e-01 | 0.038 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 9.178858e-01 | 0.037 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.183404e-01 | 0.037 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 9.199317e-01 | 0.036 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 9.218196e-01 | 0.035 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.218196e-01 | 0.035 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.226686e-01 | 0.035 | 1 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.230872e-01 | 0.035 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.230872e-01 | 0.035 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 9.255652e-01 | 0.034 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 9.255652e-01 | 0.034 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.255652e-01 | 0.034 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 9.278873e-01 | 0.033 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 9.291315e-01 | 0.032 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 9.303736e-01 | 0.031 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 9.325272e-01 | 0.030 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 9.325272e-01 | 0.030 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.325272e-01 | 0.030 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.325272e-01 | 0.030 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 9.344384e-01 | 0.029 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 9.357604e-01 | 0.029 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.357604e-01 | 0.029 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.388388e-01 | 0.027 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 9.388388e-01 | 0.027 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 9.417699e-01 | 0.026 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.445607e-01 | 0.025 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 9.464035e-01 | 0.024 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 9.472179e-01 | 0.024 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 9.472179e-01 | 0.024 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 9.472179e-01 | 0.024 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.477480e-01 | 0.023 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 9.497479e-01 | 0.022 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.497479e-01 | 0.022 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.512350e-01 | 0.022 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 9.544475e-01 | 0.020 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.544475e-01 | 0.020 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.546369e-01 | 0.020 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.562376e-01 | 0.019 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 9.566328e-01 | 0.019 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 9.566340e-01 | 0.019 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.566340e-01 | 0.019 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.602800e-01 | 0.018 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 9.606927e-01 | 0.017 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.607854e-01 | 0.017 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.613296e-01 | 0.017 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 9.625775e-01 | 0.017 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.628875e-01 | 0.016 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 9.643720e-01 | 0.016 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.643720e-01 | 0.016 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.643720e-01 | 0.016 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.660806e-01 | 0.015 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 9.677073e-01 | 0.014 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.698149e-01 | 0.013 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.707308e-01 | 0.013 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.722215e-01 | 0.012 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 9.744425e-01 | 0.011 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.747441e-01 | 0.011 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.782078e-01 | 0.010 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.782078e-01 | 0.010 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.792535e-01 | 0.009 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.792535e-01 | 0.009 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.792535e-01 | 0.009 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.802491e-01 | 0.009 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 9.802491e-01 | 0.009 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.807941e-01 | 0.008 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 9.811969e-01 | 0.008 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.826720e-01 | 0.008 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.827458e-01 | 0.008 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 9.829586e-01 | 0.007 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.852967e-01 | 0.006 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.858272e-01 | 0.006 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.869828e-01 | 0.006 | 1 | 1 |
| Visual phototransduction | R-HSA-2187338 | 9.873359e-01 | 0.006 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 9.890556e-01 | 0.005 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.890556e-01 | 0.005 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 9.900816e-01 | 0.004 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.900816e-01 | 0.004 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.901610e-01 | 0.004 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.905580e-01 | 0.004 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.905580e-01 | 0.004 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.910116e-01 | 0.004 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 9.914213e-01 | 0.004 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 9.914434e-01 | 0.004 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.915755e-01 | 0.004 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.916366e-01 | 0.004 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.922458e-01 | 0.003 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 9.924332e-01 | 0.003 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.933107e-01 | 0.003 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.939382e-01 | 0.003 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.942494e-01 | 0.003 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.947709e-01 | 0.002 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.954894e-01 | 0.002 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.954977e-01 | 0.002 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.957005e-01 | 0.002 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 9.961092e-01 | 0.002 | 0 | 0 |
| Translation | R-HSA-72766 | 9.968256e-01 | 0.001 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 9.971053e-01 | 0.001 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.971375e-01 | 0.001 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.975033e-01 | 0.001 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.978055e-01 | 0.001 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.978686e-01 | 0.001 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.980217e-01 | 0.001 | 1 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.985667e-01 | 0.001 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.988088e-01 | 0.001 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 9.988088e-01 | 0.001 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 9.988718e-01 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.989208e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.991568e-01 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 9.991575e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.992729e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.993404e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.994167e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.994963e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.995397e-01 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 9.996702e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.997424e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.997665e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 9.997667e-01 | 0.000 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.997689e-01 | 0.000 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 9.997780e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.999030e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999379e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.999407e-01 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 9.999489e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999566e-01 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.999811e-01 | 0.000 | 1 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.999931e-01 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.999989e-01 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.999995e-01 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 4.940492e-14 | 13.306 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 1.753153e-12 | 11.756 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 2.445488e-12 | 11.612 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 7.697287e-12 | 11.114 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.258238e-11 | 10.900 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 6.306911e-11 | 10.200 | 0 | 0 |
| M Phase | R-HSA-68886 | 6.495551e-10 | 9.187 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 3.155069e-09 | 8.501 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.214549e-08 | 7.916 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 3.326541e-08 | 7.478 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 5.117452e-08 | 7.291 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 9.173367e-08 | 7.037 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.326831e-07 | 6.877 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 1.452429e-07 | 6.838 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 4.165593e-07 | 6.380 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 5.296046e-07 | 6.276 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 6.855111e-07 | 6.164 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 1.251154e-06 | 5.903 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 1.300878e-06 | 5.886 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 1.300878e-06 | 5.886 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.396855e-06 | 5.855 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 2.359475e-06 | 5.627 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 3.878328e-06 | 5.411 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 8.764097e-06 | 5.057 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.116447e-05 | 4.952 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.151030e-05 | 4.939 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.742821e-05 | 4.759 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 1.742821e-05 | 4.759 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 1.801429e-05 | 4.744 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 2.129903e-05 | 4.672 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 2.438900e-05 | 4.613 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 2.438900e-05 | 4.613 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 2.588875e-05 | 4.587 | 0 | 0 |
| Kinesins | R-HSA-983189 | 2.878233e-05 | 4.541 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 3.211265e-05 | 4.493 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 3.359792e-05 | 4.474 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 3.459975e-05 | 4.461 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 3.691188e-05 | 4.433 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 3.805353e-05 | 4.420 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 4.576353e-05 | 4.339 | 1 | 0 |
| Cell junction organization | R-HSA-446728 | 4.530867e-05 | 4.344 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 4.758435e-05 | 4.323 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 5.057523e-05 | 4.296 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 4.966888e-05 | 4.304 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 7.160721e-05 | 4.145 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 7.176817e-05 | 4.144 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 8.884337e-05 | 4.051 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 9.079021e-05 | 4.042 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 9.435559e-05 | 4.025 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 1.011957e-04 | 3.995 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.126901e-04 | 3.948 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.234877e-04 | 3.908 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.228363e-04 | 3.911 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.307647e-04 | 3.884 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.423611e-04 | 3.847 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.423611e-04 | 3.847 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 1.390646e-04 | 3.857 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 1.806093e-04 | 3.743 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 1.893567e-04 | 3.723 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 2.132053e-04 | 3.671 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 1.990501e-04 | 3.701 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 2.078675e-04 | 3.682 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 2.190715e-04 | 3.659 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 2.169065e-04 | 3.664 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 2.061264e-04 | 3.686 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 2.191568e-04 | 3.659 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 2.197437e-04 | 3.658 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 2.436449e-04 | 3.613 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 2.432927e-04 | 3.614 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 2.758339e-04 | 3.559 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 2.780306e-04 | 3.556 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 3.531630e-04 | 3.452 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 3.564806e-04 | 3.448 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 3.826499e-04 | 3.417 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 3.844878e-04 | 3.415 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 3.989394e-04 | 3.399 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 4.033483e-04 | 3.394 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 3.906016e-04 | 3.408 | 1 | 1 |
| Cell Cycle Checkpoints | R-HSA-69620 | 4.443999e-04 | 3.352 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 4.560169e-04 | 3.341 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 4.750494e-04 | 3.323 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 4.846129e-04 | 3.315 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 5.141980e-04 | 3.289 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 5.141980e-04 | 3.289 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 5.066904e-04 | 3.295 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 5.141980e-04 | 3.289 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 5.531595e-04 | 3.257 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 5.531595e-04 | 3.257 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 5.541853e-04 | 3.256 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 5.722848e-04 | 3.242 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 5.608041e-04 | 3.251 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 5.972895e-04 | 3.224 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 5.977243e-04 | 3.223 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 6.428865e-04 | 3.192 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 6.981348e-04 | 3.156 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 6.979758e-04 | 3.156 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 6.976414e-04 | 3.156 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 7.168919e-04 | 3.145 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 7.298103e-04 | 3.137 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 7.298103e-04 | 3.137 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 7.839438e-04 | 3.106 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 8.534666e-04 | 3.069 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 9.134339e-04 | 3.039 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 9.513996e-04 | 3.022 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 9.614374e-04 | 3.017 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 1.113894e-03 | 2.953 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 1.241268e-03 | 2.906 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 1.171359e-03 | 2.931 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 1.238318e-03 | 2.907 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.237206e-03 | 2.908 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 1.315142e-03 | 2.881 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 1.315142e-03 | 2.881 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 1.315142e-03 | 2.881 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 1.315142e-03 | 2.881 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.321721e-03 | 2.879 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.331082e-03 | 2.876 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 1.451594e-03 | 2.838 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.474725e-03 | 2.831 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 1.485616e-03 | 2.828 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 1.644690e-03 | 2.784 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 1.742620e-03 | 2.759 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 1.685861e-03 | 2.773 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 1.690126e-03 | 2.772 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 1.681565e-03 | 2.774 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.881769e-03 | 2.725 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 1.917081e-03 | 2.717 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 2.061280e-03 | 2.686 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 2.077377e-03 | 2.682 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 2.077377e-03 | 2.682 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 2.111792e-03 | 2.675 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 2.174496e-03 | 2.663 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 2.296509e-03 | 2.639 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 2.197443e-03 | 2.658 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 2.277068e-03 | 2.643 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 2.321699e-03 | 2.634 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 2.324751e-03 | 2.634 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 2.421480e-03 | 2.616 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 2.563930e-03 | 2.591 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 2.678014e-03 | 2.572 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 2.717827e-03 | 2.566 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 2.727010e-03 | 2.564 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 2.894111e-03 | 2.538 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 3.164961e-03 | 2.500 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 3.152459e-03 | 2.501 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 3.069283e-03 | 2.513 | 1 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 3.177882e-03 | 2.498 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 3.264398e-03 | 2.486 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 3.316986e-03 | 2.479 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 3.364960e-03 | 2.473 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 3.522549e-03 | 2.453 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 3.522549e-03 | 2.453 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 3.797800e-03 | 2.420 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 4.314128e-03 | 2.365 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 4.429553e-03 | 2.354 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 4.477123e-03 | 2.349 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 4.108957e-03 | 2.386 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 4.284852e-03 | 2.368 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 4.477123e-03 | 2.349 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 4.431572e-03 | 2.353 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 4.477655e-03 | 2.349 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 4.540652e-03 | 2.343 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 4.564679e-03 | 2.341 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 4.586545e-03 | 2.339 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 5.212947e-03 | 2.283 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 5.212947e-03 | 2.283 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 5.212947e-03 | 2.283 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 5.212947e-03 | 2.283 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 5.212947e-03 | 2.283 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 5.212947e-03 | 2.283 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 5.212947e-03 | 2.283 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 5.212947e-03 | 2.283 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 5.212947e-03 | 2.283 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 5.212947e-03 | 2.283 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 5.212947e-03 | 2.283 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 5.039510e-03 | 2.298 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 5.210981e-03 | 2.283 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 4.892440e-03 | 2.310 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 4.957361e-03 | 2.305 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 5.109779e-03 | 2.292 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 5.159815e-03 | 2.287 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 5.177527e-03 | 2.286 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 5.232548e-03 | 2.281 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 5.240244e-03 | 2.281 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 5.398716e-03 | 2.268 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 5.489523e-03 | 2.260 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 5.448570e-03 | 2.264 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 5.348699e-03 | 2.272 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 5.348699e-03 | 2.272 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 5.854836e-03 | 2.232 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 5.489523e-03 | 2.260 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 5.767429e-03 | 2.239 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 5.862563e-03 | 2.232 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 5.280400e-03 | 2.277 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 5.351745e-03 | 2.272 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 5.984154e-03 | 2.223 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 6.056609e-03 | 2.218 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 6.056609e-03 | 2.218 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 6.056609e-03 | 2.218 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 6.288035e-03 | 2.201 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 6.320158e-03 | 2.199 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 6.369983e-03 | 2.196 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 6.705445e-03 | 2.174 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 6.735855e-03 | 2.172 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 6.735855e-03 | 2.172 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 6.868988e-03 | 2.163 | 1 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 6.909606e-03 | 2.161 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 7.005862e-03 | 2.155 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 7.054737e-03 | 2.152 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 8.010710e-03 | 2.096 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 8.010710e-03 | 2.096 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 8.058420e-03 | 2.094 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 8.114537e-03 | 2.091 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 8.114537e-03 | 2.091 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 8.010710e-03 | 2.096 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 7.904391e-03 | 2.102 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 7.645864e-03 | 2.117 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 8.114537e-03 | 2.091 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 8.276769e-03 | 2.082 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 8.321186e-03 | 2.080 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 8.818961e-03 | 2.055 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 9.245414e-03 | 2.034 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 9.389271e-03 | 2.027 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 9.428920e-03 | 2.026 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 9.462264e-03 | 2.024 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 1.008903e-02 | 1.996 | 1 | 1 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 1.014990e-02 | 1.994 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 1.014990e-02 | 1.994 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 1.017921e-02 | 1.992 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.018999e-02 | 1.992 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 1.024967e-02 | 1.989 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.032404e-02 | 1.986 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 1.039256e-02 | 1.983 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 1.042990e-02 | 1.982 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 1.199467e-02 | 1.921 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.163805e-02 | 1.934 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 1.179654e-02 | 1.928 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 1.152999e-02 | 1.938 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 1.199467e-02 | 1.921 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 1.074656e-02 | 1.969 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.166399e-02 | 1.933 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.189604e-02 | 1.925 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 1.059971e-02 | 1.975 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 1.113721e-02 | 1.953 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 1.199467e-02 | 1.921 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 1.214890e-02 | 1.915 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 1.230492e-02 | 1.910 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.233435e-02 | 1.909 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 1.246835e-02 | 1.904 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 1.258614e-02 | 1.900 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 1.258614e-02 | 1.900 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 1.282801e-02 | 1.892 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 1.282801e-02 | 1.892 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 1.311193e-02 | 1.882 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 1.317648e-02 | 1.880 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 1.317648e-02 | 1.880 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.326694e-02 | 1.877 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 1.341040e-02 | 1.873 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.358034e-02 | 1.867 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 1.380117e-02 | 1.860 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 1.382604e-02 | 1.859 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.427231e-02 | 1.846 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 1.438528e-02 | 1.842 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 1.438528e-02 | 1.842 | 1 | 0 |
| Signaling by ALK | R-HSA-201556 | 1.438528e-02 | 1.842 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 1.459560e-02 | 1.836 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 1.497862e-02 | 1.825 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 1.518263e-02 | 1.819 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 1.518263e-02 | 1.819 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 1.518263e-02 | 1.819 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 1.807970e-02 | 1.743 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 1.564953e-02 | 1.805 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.556941e-02 | 1.808 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 1.780980e-02 | 1.749 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 1.780980e-02 | 1.749 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.788609e-02 | 1.747 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 1.706296e-02 | 1.768 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 1.707300e-02 | 1.768 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.807970e-02 | 1.743 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 1.769900e-02 | 1.752 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 1.800254e-02 | 1.745 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 1.789899e-02 | 1.747 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 1.706296e-02 | 1.768 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 1.789899e-02 | 1.747 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 1.815807e-02 | 1.741 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 1.826903e-02 | 1.738 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.836347e-02 | 1.736 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 1.846847e-02 | 1.734 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 1.882009e-02 | 1.725 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 1.898706e-02 | 1.722 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 1.928496e-02 | 1.715 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 1.929307e-02 | 1.715 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 1.941806e-02 | 1.712 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 1.964211e-02 | 1.707 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 1.984364e-02 | 1.702 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 2.005814e-02 | 1.698 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 2.027469e-02 | 1.693 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 2.027469e-02 | 1.693 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 2.133287e-02 | 1.671 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 2.206602e-02 | 1.656 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 2.209041e-02 | 1.656 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 2.235990e-02 | 1.651 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 2.269858e-02 | 1.644 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 2.269858e-02 | 1.644 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 2.292833e-02 | 1.640 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 2.485826e-02 | 1.605 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 2.489519e-02 | 1.604 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 2.543127e-02 | 1.595 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 2.543127e-02 | 1.595 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 2.543127e-02 | 1.595 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 2.648644e-02 | 1.577 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 3.180687e-02 | 1.497 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 3.180687e-02 | 1.497 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 3.180687e-02 | 1.497 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 3.180687e-02 | 1.497 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 2.830898e-02 | 1.548 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 2.957446e-02 | 1.529 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 2.855120e-02 | 1.544 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 2.855120e-02 | 1.544 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 3.160983e-02 | 1.500 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 2.984589e-02 | 1.525 | 0 | 0 |
| Protein folding | R-HSA-391251 | 3.075987e-02 | 1.512 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 3.131011e-02 | 1.504 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 3.218207e-02 | 1.492 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 2.740574e-02 | 1.562 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 3.259588e-02 | 1.487 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 3.088891e-02 | 1.510 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 3.171649e-02 | 1.499 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 2.859716e-02 | 1.544 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 3.209942e-02 | 1.494 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 2.855120e-02 | 1.544 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 3.296694e-02 | 1.482 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 3.296694e-02 | 1.482 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 3.296694e-02 | 1.482 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 3.296694e-02 | 1.482 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 3.302651e-02 | 1.481 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 3.318174e-02 | 1.479 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 3.334526e-02 | 1.477 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 3.388395e-02 | 1.470 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 3.398279e-02 | 1.469 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 3.486516e-02 | 1.458 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 3.564074e-02 | 1.448 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 3.596148e-02 | 1.444 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 3.596148e-02 | 1.444 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 3.611871e-02 | 1.442 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 3.650315e-02 | 1.438 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 3.668541e-02 | 1.436 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 3.678820e-02 | 1.434 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 3.818931e-02 | 1.418 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 3.838611e-02 | 1.416 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 3.838611e-02 | 1.416 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 3.838611e-02 | 1.416 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 3.849626e-02 | 1.415 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 3.877616e-02 | 1.411 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 3.916657e-02 | 1.407 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 3.916657e-02 | 1.407 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 3.918045e-02 | 1.407 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 4.629271e-02 | 1.334 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 4.629271e-02 | 1.334 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 4.629271e-02 | 1.334 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 4.629271e-02 | 1.334 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 4.629271e-02 | 1.334 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 4.629271e-02 | 1.334 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 4.940686e-02 | 1.306 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 4.940686e-02 | 1.306 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 4.176175e-02 | 1.379 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 4.176175e-02 | 1.379 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 4.552757e-02 | 1.342 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 4.552757e-02 | 1.342 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 4.654814e-02 | 1.332 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 4.602988e-02 | 1.337 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 4.602988e-02 | 1.337 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 4.463931e-02 | 1.350 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 4.463931e-02 | 1.350 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 4.276225e-02 | 1.369 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 4.063032e-02 | 1.391 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.783230e-02 | 1.320 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 4.486381e-02 | 1.348 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 4.395165e-02 | 1.357 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 4.063032e-02 | 1.391 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 4.771792e-02 | 1.321 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 4.242840e-02 | 1.372 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 4.602988e-02 | 1.337 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 4.552757e-02 | 1.342 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 4.940686e-02 | 1.306 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 4.940686e-02 | 1.306 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 4.196127e-02 | 1.377 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 4.959611e-02 | 1.305 | 1 | 0 |
| S Phase | R-HSA-69242 | 4.492515e-02 | 1.348 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 4.940686e-02 | 1.306 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 4.276225e-02 | 1.369 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 4.501068e-02 | 1.347 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 4.940686e-02 | 1.306 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 4.654814e-02 | 1.332 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 4.654814e-02 | 1.332 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 4.501068e-02 | 1.347 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 4.063032e-02 | 1.391 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 4.613710e-02 | 1.336 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 4.783230e-02 | 1.320 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 4.552757e-02 | 1.342 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 4.463931e-02 | 1.350 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 4.046679e-02 | 1.393 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 4.156846e-02 | 1.381 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 4.986811e-02 | 1.302 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 5.079509e-02 | 1.294 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 5.144030e-02 | 1.289 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 5.163190e-02 | 1.287 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 5.205965e-02 | 1.283 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 5.317146e-02 | 1.274 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 5.317146e-02 | 1.274 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 5.329079e-02 | 1.273 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 5.363152e-02 | 1.271 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 5.363152e-02 | 1.271 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 5.363152e-02 | 1.271 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 5.484857e-02 | 1.261 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 5.497059e-02 | 1.260 | 0 | 0 |
| Inhibition of nitric oxide production | R-HSA-9636249 | 5.497059e-02 | 1.260 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 5.549477e-02 | 1.256 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 5.557097e-02 | 1.255 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 5.573968e-02 | 1.254 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 5.604808e-02 | 1.251 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 5.613730e-02 | 1.251 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 5.643978e-02 | 1.248 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 5.643978e-02 | 1.248 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 5.643978e-02 | 1.248 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 5.643978e-02 | 1.248 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 5.643978e-02 | 1.248 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 5.643978e-02 | 1.248 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 5.643978e-02 | 1.248 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 5.718764e-02 | 1.243 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 5.846227e-02 | 1.233 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 5.846227e-02 | 1.233 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 5.846227e-02 | 1.233 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 5.846227e-02 | 1.233 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 5.846227e-02 | 1.233 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 5.846227e-02 | 1.233 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 5.846227e-02 | 1.233 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 5.847659e-02 | 1.233 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 5.977402e-02 | 1.223 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 5.977402e-02 | 1.223 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 5.978758e-02 | 1.223 | 1 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 5.999976e-02 | 1.222 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 6.048973e-02 | 1.218 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 6.086983e-02 | 1.216 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 6.241447e-02 | 1.205 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 6.318102e-02 | 1.199 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 6.319330e-02 | 1.199 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 6.372757e-02 | 1.196 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 6.472438e-02 | 1.189 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 6.504069e-02 | 1.187 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 6.669589e-02 | 1.176 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 6.755297e-02 | 1.170 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 6.755297e-02 | 1.170 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 6.870527e-02 | 1.163 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 6.959093e-02 | 1.157 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 6.959093e-02 | 1.157 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 6.959093e-02 | 1.157 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 6.959093e-02 | 1.157 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 6.959093e-02 | 1.157 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 8.415659e-02 | 1.075 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 8.415659e-02 | 1.075 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 9.336047e-02 | 1.030 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 9.336047e-02 | 1.030 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 7.372274e-02 | 1.132 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 7.372274e-02 | 1.132 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 7.337827e-02 | 1.134 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 8.731602e-02 | 1.059 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 8.731602e-02 | 1.059 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 8.066594e-02 | 1.093 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 7.189563e-02 | 1.143 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 8.338841e-02 | 1.079 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 8.766965e-02 | 1.057 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 7.268363e-02 | 1.139 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 9.279566e-02 | 1.032 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 9.027250e-02 | 1.044 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 8.642803e-02 | 1.063 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 7.475022e-02 | 1.126 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 9.260372e-02 | 1.033 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 8.070087e-02 | 1.093 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 7.446097e-02 | 1.128 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 7.819193e-02 | 1.107 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 9.336047e-02 | 1.030 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 7.372274e-02 | 1.132 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 7.644537e-02 | 1.117 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 7.264887e-02 | 1.139 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 9.026588e-02 | 1.044 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 8.008265e-02 | 1.096 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 7.977350e-02 | 1.098 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 8.415659e-02 | 1.075 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 8.070087e-02 | 1.093 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 7.478931e-02 | 1.126 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 8.731602e-02 | 1.059 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 7.429774e-02 | 1.129 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 7.644537e-02 | 1.117 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 7.264887e-02 | 1.139 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 8.512741e-02 | 1.070 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 7.446097e-02 | 1.128 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 8.415659e-02 | 1.075 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 7.446097e-02 | 1.128 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 8.029666e-02 | 1.095 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 8.338841e-02 | 1.079 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 7.920152e-02 | 1.101 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 9.260372e-02 | 1.033 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 8.523262e-02 | 1.069 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 8.642803e-02 | 1.063 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 8.642803e-02 | 1.063 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 8.466978e-02 | 1.072 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 7.254541e-02 | 1.139 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 8.642803e-02 | 1.063 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 9.337980e-02 | 1.030 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 9.337980e-02 | 1.030 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 9.337980e-02 | 1.030 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 9.337980e-02 | 1.030 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 9.337980e-02 | 1.030 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 9.337980e-02 | 1.030 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 9.337980e-02 | 1.030 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 9.337980e-02 | 1.030 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 9.355804e-02 | 1.029 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 9.355804e-02 | 1.029 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 9.355804e-02 | 1.029 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 9.355804e-02 | 1.029 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 9.355804e-02 | 1.029 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 9.395120e-02 | 1.027 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 9.437047e-02 | 1.025 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 9.437047e-02 | 1.025 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 9.498914e-02 | 1.022 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 9.605211e-02 | 1.017 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 9.605211e-02 | 1.017 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 9.605211e-02 | 1.017 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 9.640676e-02 | 1.016 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 9.688347e-02 | 1.014 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 9.798905e-02 | 1.009 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 1.000904e-01 | 1.000 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 1.000904e-01 | 1.000 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 1.008193e-01 | 0.996 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.017143e-01 | 0.993 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 1.017143e-01 | 0.993 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 1.017143e-01 | 0.993 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 1.017143e-01 | 0.993 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 1.017170e-01 | 0.993 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 1.035143e-01 | 0.985 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 1.042291e-01 | 0.982 | 0 | 0 |
| Translation | R-HSA-72766 | 1.043516e-01 | 0.982 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 1.051223e-01 | 0.978 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.071353e-01 | 0.970 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 1.089211e-01 | 0.963 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 1.089639e-01 | 0.963 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 1.089639e-01 | 0.963 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.090759e-01 | 0.962 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 1.090759e-01 | 0.962 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 1.090759e-01 | 0.962 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 1.090759e-01 | 0.962 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 1.090759e-01 | 0.962 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 1.090759e-01 | 0.962 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 1.097590e-01 | 0.960 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 1.097590e-01 | 0.960 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 1.122384e-01 | 0.950 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 1.135118e-01 | 0.945 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 1.141862e-01 | 0.942 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 1.154480e-01 | 0.938 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 1.154480e-01 | 0.938 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 1.154480e-01 | 0.938 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 1.158278e-01 | 0.936 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 1.158278e-01 | 0.936 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 1.158278e-01 | 0.936 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 1.158278e-01 | 0.936 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 1.158278e-01 | 0.936 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 1.177211e-01 | 0.929 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.177211e-01 | 0.929 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 1.177211e-01 | 0.929 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 1.185469e-01 | 0.926 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 1.185469e-01 | 0.926 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 1.185469e-01 | 0.926 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 1.194224e-01 | 0.923 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 1.194224e-01 | 0.923 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 1.194224e-01 | 0.923 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 1.194534e-01 | 0.923 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 1.194534e-01 | 0.923 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 1.204343e-01 | 0.919 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 1.204343e-01 | 0.919 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 1.204343e-01 | 0.919 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 1.215812e-01 | 0.915 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 1.222225e-01 | 0.913 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 1.222225e-01 | 0.913 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 1.222225e-01 | 0.913 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 1.240633e-01 | 0.906 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 1.240633e-01 | 0.906 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 1.240633e-01 | 0.906 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 1.251946e-01 | 0.902 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.251946e-01 | 0.902 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 1.251946e-01 | 0.902 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 1.251946e-01 | 0.902 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 1.257755e-01 | 0.900 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 1.264298e-01 | 0.898 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 1.297231e-01 | 0.887 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 1.297231e-01 | 0.887 | 0 | 0 |
| Drug resistance of FLT3 mutants | R-HSA-9702506 | 1.564701e-01 | 0.806 | 0 | 0 |
| FLT3 mutants bind TKIs | R-HSA-9702509 | 1.564701e-01 | 0.806 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.564701e-01 | 0.806 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p14ARF Defects | R-HSA-9646303 | 1.564701e-01 | 0.806 | 0 | 0 |
| quizartinib-resistant FLT3 mutants | R-HSA-9702620 | 1.564701e-01 | 0.806 | 0 | 0 |
| tamatinib-resistant FLT3 mutants | R-HSA-9703009 | 1.564701e-01 | 0.806 | 0 | 0 |
| sorafenib-resistant FLT3 mutants | R-HSA-9702624 | 1.564701e-01 | 0.806 | 0 | 0 |
| midostaurin-resistant FLT3 mutants | R-HSA-9702600 | 1.564701e-01 | 0.806 | 0 | 0 |
| semaxanib-resistant FLT3 mutants | R-HSA-9702577 | 1.564701e-01 | 0.806 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.564701e-01 | 0.806 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects | R-HSA-9646304 | 1.564701e-01 | 0.806 | 0 | 0 |
| linifanib-resistant FLT3 mutants | R-HSA-9702998 | 1.564701e-01 | 0.806 | 0 | 0 |
| sunitinib-resistant FLT3 mutants | R-HSA-9702632 | 1.564701e-01 | 0.806 | 0 | 0 |
| crenolanib-resistant FLT3 mutants | R-HSA-9702581 | 1.564701e-01 | 0.806 | 0 | 0 |
| ponatinib-resistant FLT3 mutants | R-HSA-9702614 | 1.564701e-01 | 0.806 | 0 | 0 |
| gilteritinib-resistant FLT3 mutants | R-HSA-9702590 | 1.564701e-01 | 0.806 | 0 | 0 |
| pexidartinib-resistant FLT3 mutants | R-HSA-9702605 | 1.564701e-01 | 0.806 | 0 | 0 |
| KW2449-resistant FLT3 mutants | R-HSA-9702569 | 1.564701e-01 | 0.806 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.564701e-01 | 0.806 | 0 | 0 |
| tandutinib-resistant FLT3 mutants | R-HSA-9702636 | 1.564701e-01 | 0.806 | 0 | 0 |
| lestaurtinib-resistant FLT3 mutants | R-HSA-9702596 | 1.564701e-01 | 0.806 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 1.490829e-01 | 0.827 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 1.490829e-01 | 0.827 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 1.490829e-01 | 0.827 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 1.490829e-01 | 0.827 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 1.571767e-01 | 0.804 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 1.571767e-01 | 0.804 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 1.571767e-01 | 0.804 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 1.504414e-01 | 0.823 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 1.403591e-01 | 0.853 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 1.403591e-01 | 0.853 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 1.403591e-01 | 0.853 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 1.829515e-01 | 0.738 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 1.829515e-01 | 0.738 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 1.669347e-01 | 0.777 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 1.386059e-01 | 0.858 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 1.953045e-01 | 0.709 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 1.953045e-01 | 0.709 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 1.953045e-01 | 0.709 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 1.760347e-01 | 0.754 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 1.591809e-01 | 0.798 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 1.443347e-01 | 0.841 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 1.810453e-01 | 0.742 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 1.810453e-01 | 0.742 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 1.634107e-01 | 0.787 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 1.479665e-01 | 0.830 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 1.668530e-01 | 0.778 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 1.844090e-01 | 0.734 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 1.508643e-01 | 0.821 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 1.643403e-01 | 0.784 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.457915e-01 | 0.836 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 1.780866e-01 | 0.749 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 1.537543e-01 | 0.813 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 1.766067e-01 | 0.753 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 1.405694e-01 | 0.852 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 1.403591e-01 | 0.853 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 1.657701e-01 | 0.780 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 1.550168e-01 | 0.810 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 1.559927e-01 | 0.807 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 1.403591e-01 | 0.853 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 1.821761e-01 | 0.740 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 1.657701e-01 | 0.780 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 1.835525e-01 | 0.736 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 1.520905e-01 | 0.818 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 1.835820e-01 | 0.736 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 1.688941e-01 | 0.772 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 1.329299e-01 | 0.876 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 1.669347e-01 | 0.777 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 1.508643e-01 | 0.821 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 1.597429e-01 | 0.797 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 1.701007e-01 | 0.769 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 1.546732e-01 | 0.811 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 1.835525e-01 | 0.736 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 1.835525e-01 | 0.736 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 1.844090e-01 | 0.734 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 1.403591e-01 | 0.853 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 1.520905e-01 | 0.818 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 1.669347e-01 | 0.777 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 1.835820e-01 | 0.736 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 1.632174e-01 | 0.787 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 1.668530e-01 | 0.778 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 1.403591e-01 | 0.853 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 1.637576e-01 | 0.786 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 1.490829e-01 | 0.827 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 1.490829e-01 | 0.827 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 1.760347e-01 | 0.754 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 1.409797e-01 | 0.851 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 1.669347e-01 | 0.777 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 1.443347e-01 | 0.841 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 1.443347e-01 | 0.841 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 1.810453e-01 | 0.742 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 1.726270e-01 | 0.763 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 1.504414e-01 | 0.823 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.520905e-01 | 0.818 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 1.363379e-01 | 0.865 | 0 | 0 |
| Depurination | R-HSA-73927 | 1.512863e-01 | 0.820 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 1.516667e-01 | 0.819 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 1.516667e-01 | 0.819 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 1.973741e-01 | 0.705 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 1.987403e-01 | 0.702 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 1.988340e-01 | 0.702 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 1.990401e-01 | 0.701 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 1.990401e-01 | 0.701 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 1.990401e-01 | 0.701 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 2.007904e-01 | 0.697 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 2.007904e-01 | 0.697 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 2.013905e-01 | 0.696 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 2.027604e-01 | 0.693 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 2.027604e-01 | 0.693 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 2.027604e-01 | 0.693 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 2.027604e-01 | 0.693 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 2.028109e-01 | 0.693 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 2.034902e-01 | 0.691 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 2.040822e-01 | 0.690 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 2.040822e-01 | 0.690 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 2.040822e-01 | 0.690 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 2.041748e-01 | 0.690 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 2.041748e-01 | 0.690 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 2.047613e-01 | 0.689 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 2.047613e-01 | 0.689 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 2.047613e-01 | 0.689 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 2.069311e-01 | 0.684 | 0 | 0 |
| Signaling by FGFR1 amplification mutants | R-HSA-1839120 | 2.095549e-01 | 0.679 | 0 | 0 |
| TRKA activation by NGF | R-HSA-187042 | 2.095549e-01 | 0.679 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 2.095549e-01 | 0.679 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 2.095549e-01 | 0.679 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 2.095549e-01 | 0.679 | 0 | 0 |
| IRAK4 deficiency (TLR5) | R-HSA-5603037 | 2.095549e-01 | 0.679 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 2.095549e-01 | 0.679 | 0 | 0 |
| STAT6-mediated induction of chemokines | R-HSA-3249367 | 2.095549e-01 | 0.679 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 2.095549e-01 | 0.679 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 2.100537e-01 | 0.678 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 2.116733e-01 | 0.674 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 2.122182e-01 | 0.673 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 2.175018e-01 | 0.663 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 2.175018e-01 | 0.663 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 2.175018e-01 | 0.663 | 0 | 0 |
| Regulation of gene expression in early pancreatic precursor cells | R-HSA-210747 | 2.175018e-01 | 0.663 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 2.175018e-01 | 0.663 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 2.195607e-01 | 0.658 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 2.884648e-01 | 0.540 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9632697 | 2.884648e-01 | 0.540 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH3 | R-HSA-5632927 | 2.884648e-01 | 0.540 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 2.884648e-01 | 0.540 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9630791 | 2.884648e-01 | 0.540 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 2.884648e-01 | 0.540 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 2.884648e-01 | 0.540 | 0 | 0 |
| Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR) | R-HSA-5619110 | 2.884648e-01 | 0.540 | 0 | 0 |
| SARS-CoV-1 targets PDZ proteins in cell-cell junction | R-HSA-9692912 | 2.884648e-01 | 0.540 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function | R-HSA-9645722 | 2.884648e-01 | 0.540 | 0 | 0 |
| Defective GALM causes GALAC4 | R-HSA-9931929 | 2.884648e-01 | 0.540 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 2.884648e-01 | 0.540 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 2.884648e-01 | 0.540 | 0 | 0 |
| Defective F8 binding to von Willebrand factor | R-HSA-9672393 | 2.884648e-01 | 0.540 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 2.884648e-01 | 0.540 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 2.719409e-01 | 0.566 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 2.719409e-01 | 0.566 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 2.719409e-01 | 0.566 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 2.719409e-01 | 0.566 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 2.719409e-01 | 0.566 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 2.719409e-01 | 0.566 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 2.719409e-01 | 0.566 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 2.719409e-01 | 0.566 | 0 | 0 |
| FGFR4 mutant receptor activation | R-HSA-1839128 | 3.998115e-01 | 0.398 | 0 | 0 |
| Nef mediated downregulation of CD28 cell surface expression | R-HSA-164939 | 3.998115e-01 | 0.398 | 0 | 0 |
| Abasic sugar-phosphate removal via the single-nucleotide replacement pathway | R-HSA-73930 | 3.998115e-01 | 0.398 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 3.998115e-01 | 0.398 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5619081 | 3.998115e-01 | 0.398 | 0 | 0 |
| Defective VWF binding to collagen type I | R-HSA-9845622 | 3.998115e-01 | 0.398 | 0 | 0 |
| TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P | R-HSA-6791462 | 3.998115e-01 | 0.398 | 0 | 0 |
| Defective GFPT1 causes CMSTA1 | R-HSA-4085023 | 3.998115e-01 | 0.398 | 0 | 0 |
| Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | R-HSA-5083628 | 3.998115e-01 | 0.398 | 0 | 0 |
| TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P | R-HSA-6791055 | 3.998115e-01 | 0.398 | 0 | 0 |
| Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM) | R-HSA-5619045 | 3.998115e-01 | 0.398 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 3.998115e-01 | 0.398 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 3.998115e-01 | 0.398 | 0 | 0 |
| MyD88 deficiency (TLR5) | R-HSA-5602680 | 3.998115e-01 | 0.398 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5660724 | 3.998115e-01 | 0.398 | 0 | 0 |
| Defective APRT disrupts adenine salvage | R-HSA-9734195 | 3.998115e-01 | 0.398 | 0 | 0 |
| Defective SLC34A2 causes PALM | R-HSA-5687583 | 3.998115e-01 | 0.398 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 3.998115e-01 | 0.398 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 3.998115e-01 | 0.398 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 2.431605e-01 | 0.614 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 2.431605e-01 | 0.614 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 2.431605e-01 | 0.614 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 2.431605e-01 | 0.614 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 2.431605e-01 | 0.614 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 3.341623e-01 | 0.476 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 3.341623e-01 | 0.476 | 0 | 0 |
| IRS activation | R-HSA-74713 | 3.341623e-01 | 0.476 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 3.341623e-01 | 0.476 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 3.341623e-01 | 0.476 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 3.341623e-01 | 0.476 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 3.341623e-01 | 0.476 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 3.341623e-01 | 0.476 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 3.341623e-01 | 0.476 | 0 | 0 |
| ALKBH3 mediated reversal of alkylation damage | R-HSA-112126 | 2.886341e-01 | 0.540 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 2.886341e-01 | 0.540 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 2.886341e-01 | 0.540 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 2.886341e-01 | 0.540 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 2.886341e-01 | 0.540 | 0 | 0 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 2.536190e-01 | 0.596 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 2.251960e-01 | 0.647 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 2.251960e-01 | 0.647 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 2.279772e-01 | 0.642 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 2.563242e-01 | 0.591 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 2.563242e-01 | 0.591 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 3.346552e-01 | 0.475 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 3.346552e-01 | 0.475 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 3.346552e-01 | 0.475 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 3.346552e-01 | 0.475 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 3.947436e-01 | 0.404 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 3.947436e-01 | 0.404 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 3.947436e-01 | 0.404 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 3.947436e-01 | 0.404 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 3.947436e-01 | 0.404 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 3.947436e-01 | 0.404 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 3.947436e-01 | 0.404 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 2.556026e-01 | 0.592 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 2.268518e-01 | 0.644 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 2.268518e-01 | 0.644 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 3.287154e-01 | 0.483 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 2.531470e-01 | 0.597 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 2.840691e-01 | 0.547 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 3.805278e-01 | 0.420 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 3.805278e-01 | 0.420 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 3.211400e-01 | 0.493 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 3.211400e-01 | 0.493 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 3.211400e-01 | 0.493 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 2.458240e-01 | 0.609 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 2.733437e-01 | 0.563 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 3.131770e-01 | 0.504 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 3.131770e-01 | 0.504 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 3.131770e-01 | 0.504 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 2.619660e-01 | 0.582 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 3.542681e-01 | 0.451 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 3.542681e-01 | 0.451 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 3.542681e-01 | 0.451 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 3.542681e-01 | 0.451 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 2.975214e-01 | 0.526 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 2.975214e-01 | 0.526 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 2.975214e-01 | 0.526 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 2.900501e-01 | 0.538 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 3.427293e-01 | 0.465 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 3.427293e-01 | 0.465 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 3.427293e-01 | 0.465 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 4.256682e-01 | 0.371 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 4.256682e-01 | 0.371 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 2.453865e-01 | 0.610 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 2.453865e-01 | 0.610 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 2.828548e-01 | 0.548 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 3.320730e-01 | 0.479 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 3.320730e-01 | 0.479 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 4.048354e-01 | 0.393 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 4.048354e-01 | 0.393 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 4.048354e-01 | 0.393 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 3.875249e-01 | 0.412 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 3.875249e-01 | 0.412 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 3.725347e-01 | 0.429 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 3.725347e-01 | 0.429 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 2.807946e-01 | 0.552 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 2.990775e-01 | 0.524 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 2.990775e-01 | 0.524 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 3.371333e-01 | 0.472 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 3.479310e-01 | 0.459 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 3.865279e-01 | 0.413 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 3.865279e-01 | 0.413 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 4.206694e-01 | 0.376 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 4.423736e-01 | 0.354 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 4.423736e-01 | 0.354 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 4.423736e-01 | 0.354 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 4.423736e-01 | 0.354 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 3.008018e-01 | 0.522 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 3.469552e-01 | 0.460 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 3.977562e-01 | 0.400 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 3.426158e-01 | 0.465 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 4.070706e-01 | 0.390 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 4.374333e-01 | 0.359 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 3.943399e-01 | 0.404 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 2.372353e-01 | 0.625 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 3.542681e-01 | 0.451 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 3.471636e-01 | 0.459 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 2.709978e-01 | 0.567 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.406641e-01 | 0.619 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 3.471636e-01 | 0.459 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 4.333156e-01 | 0.363 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 3.211400e-01 | 0.493 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 2.828548e-01 | 0.548 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 2.670086e-01 | 0.573 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 4.308438e-01 | 0.366 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 3.925464e-01 | 0.406 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 3.925464e-01 | 0.406 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 3.471636e-01 | 0.459 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 4.308438e-01 | 0.366 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 3.805278e-01 | 0.420 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 3.542681e-01 | 0.451 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 4.206694e-01 | 0.376 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 3.833006e-01 | 0.416 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 4.149929e-01 | 0.382 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 2.653349e-01 | 0.576 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 2.886341e-01 | 0.540 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 2.251960e-01 | 0.647 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 3.792699e-01 | 0.421 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 3.596217e-01 | 0.444 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 3.444324e-01 | 0.463 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 2.982098e-01 | 0.525 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 2.484393e-01 | 0.605 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 2.719409e-01 | 0.566 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 2.251960e-01 | 0.647 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 3.947436e-01 | 0.404 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 2.556026e-01 | 0.592 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 2.840691e-01 | 0.547 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 4.423736e-01 | 0.354 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 4.231316e-01 | 0.374 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 3.705228e-01 | 0.431 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 3.705228e-01 | 0.431 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 3.361250e-01 | 0.473 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 4.279160e-01 | 0.369 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 3.197623e-01 | 0.495 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 2.884005e-01 | 0.540 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 2.788924e-01 | 0.555 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 3.131770e-01 | 0.504 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 4.363513e-01 | 0.360 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 2.470794e-01 | 0.607 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 2.246337e-01 | 0.649 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 3.712402e-01 | 0.430 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 2.886341e-01 | 0.540 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 2.536190e-01 | 0.596 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 2.908381e-01 | 0.536 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 2.497492e-01 | 0.602 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 3.725347e-01 | 0.429 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 4.321849e-01 | 0.364 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 3.141030e-01 | 0.503 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 3.545459e-01 | 0.450 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 2.975214e-01 | 0.526 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 3.875249e-01 | 0.412 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 2.218477e-01 | 0.654 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 4.423736e-01 | 0.354 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 3.495153e-01 | 0.457 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 2.246337e-01 | 0.649 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 3.805278e-01 | 0.420 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 3.287154e-01 | 0.483 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 3.221667e-01 | 0.492 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 3.441942e-01 | 0.463 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 3.341623e-01 | 0.476 | 0 | 0 |
| Pyrophosphate hydrolysis | R-HSA-71737 | 3.341623e-01 | 0.476 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 2.279772e-01 | 0.642 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 3.947436e-01 | 0.404 | 0 | 0 |
| VEGF binds to VEGFR leading to receptor dimerization | R-HSA-195399 | 3.947436e-01 | 0.404 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 3.287154e-01 | 0.483 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 2.828548e-01 | 0.548 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 4.206694e-01 | 0.376 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 4.138799e-01 | 0.383 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 4.411387e-01 | 0.355 | 1 | 1 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 4.308438e-01 | 0.366 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 3.843548e-01 | 0.415 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 3.581119e-01 | 0.446 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 2.990775e-01 | 0.524 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 2.246337e-01 | 0.649 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 2.556026e-01 | 0.592 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 4.423736e-01 | 0.354 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 4.013729e-01 | 0.396 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 4.327131e-01 | 0.364 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 2.925622e-01 | 0.534 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 3.287154e-01 | 0.483 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 4.048354e-01 | 0.393 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 2.925622e-01 | 0.534 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 3.865279e-01 | 0.413 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 3.950041e-01 | 0.403 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 2.431605e-01 | 0.614 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 2.431605e-01 | 0.614 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 2.908381e-01 | 0.536 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 2.908381e-01 | 0.536 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 2.908381e-01 | 0.536 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 4.256682e-01 | 0.371 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 2.605614e-01 | 0.584 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 3.330743e-01 | 0.477 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 2.531470e-01 | 0.597 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 3.860023e-01 | 0.413 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 3.575084e-01 | 0.447 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 3.977562e-01 | 0.400 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 2.629926e-01 | 0.580 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 3.052505e-01 | 0.515 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 2.788924e-01 | 0.555 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 4.290758e-01 | 0.367 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 2.759350e-01 | 0.559 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 3.775022e-01 | 0.423 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 4.333156e-01 | 0.363 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 2.884648e-01 | 0.540 | 1 | 1 |
| MTF1 activates gene expression | R-HSA-5660489 | 2.719409e-01 | 0.566 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 3.998115e-01 | 0.398 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 2.431605e-01 | 0.614 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 3.341623e-01 | 0.476 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 3.341623e-01 | 0.476 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 2.886341e-01 | 0.540 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 2.908381e-01 | 0.536 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 3.346552e-01 | 0.475 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 3.947436e-01 | 0.404 | 0 | 0 |
| VEGF ligand-receptor interactions | R-HSA-194313 | 3.947436e-01 | 0.404 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 3.287154e-01 | 0.483 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 2.531470e-01 | 0.597 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 3.052505e-01 | 0.515 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 2.692816e-01 | 0.570 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 4.024105e-01 | 0.395 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 3.833006e-01 | 0.416 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 3.925464e-01 | 0.406 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 4.149929e-01 | 0.382 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 4.149929e-01 | 0.382 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 2.466573e-01 | 0.608 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 3.471636e-01 | 0.459 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 4.374333e-01 | 0.359 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 2.506778e-01 | 0.601 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 2.251960e-01 | 0.647 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 2.431605e-01 | 0.614 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 2.567227e-01 | 0.591 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 3.668390e-01 | 0.436 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 3.977562e-01 | 0.400 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 2.788924e-01 | 0.555 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 2.520879e-01 | 0.598 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 2.395504e-01 | 0.621 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 4.374333e-01 | 0.359 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 2.719409e-01 | 0.566 | 0 | 0 |
| Inhibition of membrane repair | R-HSA-9635644 | 3.998115e-01 | 0.398 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 3.998115e-01 | 0.398 | 0 | 0 |
| PTK6 Activates STAT3 | R-HSA-8849474 | 3.341623e-01 | 0.476 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 3.805278e-01 | 0.420 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 2.628821e-01 | 0.580 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 4.070706e-01 | 0.390 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 2.908381e-01 | 0.536 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 4.374703e-01 | 0.359 | 0 | 0 |
| CASP4 inflammasome assembly | R-HSA-9948001 | 3.805278e-01 | 0.420 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 2.299517e-01 | 0.638 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 4.140392e-01 | 0.383 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 3.668390e-01 | 0.436 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 2.840691e-01 | 0.547 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 3.805278e-01 | 0.420 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 2.908381e-01 | 0.536 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 3.670291e-01 | 0.435 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 4.256682e-01 | 0.371 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 4.431728e-01 | 0.353 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 4.431728e-01 | 0.353 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 4.431728e-01 | 0.353 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 4.431728e-01 | 0.353 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 4.482491e-01 | 0.348 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 4.484204e-01 | 0.348 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 4.493272e-01 | 0.347 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 4.526749e-01 | 0.344 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 4.526749e-01 | 0.344 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 4.526749e-01 | 0.344 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 4.526749e-01 | 0.344 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 4.526749e-01 | 0.344 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 4.527955e-01 | 0.344 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 4.534822e-01 | 0.343 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 4.534822e-01 | 0.343 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 4.534822e-01 | 0.343 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 4.545358e-01 | 0.342 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 4.545358e-01 | 0.342 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 4.545358e-01 | 0.342 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 4.545358e-01 | 0.342 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 4.597969e-01 | 0.337 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 4.616987e-01 | 0.336 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 4.616987e-01 | 0.336 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 4.644089e-01 | 0.333 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 4.681824e-01 | 0.330 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 4.696010e-01 | 0.328 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 4.696010e-01 | 0.328 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 4.696010e-01 | 0.328 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 4.696010e-01 | 0.328 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 4.696010e-01 | 0.328 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 4.696010e-01 | 0.328 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 4.735252e-01 | 0.325 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 4.735252e-01 | 0.325 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 4.745535e-01 | 0.324 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 4.748474e-01 | 0.323 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 4.791670e-01 | 0.320 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 4.791670e-01 | 0.320 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 4.791670e-01 | 0.320 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 4.791670e-01 | 0.320 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 4.857668e-01 | 0.314 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 4.857668e-01 | 0.314 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 4.880761e-01 | 0.312 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 4.886562e-01 | 0.311 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 4.886562e-01 | 0.311 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 4.886562e-01 | 0.311 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 4.886562e-01 | 0.311 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 4.886562e-01 | 0.311 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 4.889722e-01 | 0.311 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 4.889722e-01 | 0.311 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 4.889722e-01 | 0.311 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 4.908070e-01 | 0.309 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 4.908070e-01 | 0.309 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 4.908070e-01 | 0.309 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 4.908070e-01 | 0.309 | 0 | 0 |
| BDNF activates NTRK2 (TRKB) signaling | R-HSA-9024909 | 4.937391e-01 | 0.307 | 0 | 0 |
| NTF4 activates NTRK2 (TRKB) signaling | R-HSA-9026357 | 4.937391e-01 | 0.307 | 0 | 0 |
| NTF3 activates NTRK2 (TRKB) signaling | R-HSA-9025046 | 4.937391e-01 | 0.307 | 0 | 0 |
| Defective ALG9 causes CDG-1l | R-HSA-4720454 | 4.937391e-01 | 0.307 | 0 | 0 |
| Defective PAPSS2 causes SEMD-PA | R-HSA-3560796 | 4.937391e-01 | 0.307 | 0 | 0 |
| Interaction between PHLDA1 and AURKA | R-HSA-8854521 | 4.937391e-01 | 0.307 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 4.937391e-01 | 0.307 | 0 | 0 |
| Enhanced cleavage of VWF variant by ADAMTS13 | R-HSA-9845619 | 4.937391e-01 | 0.307 | 0 | 0 |
| Defective VWF cleavage by ADAMTS13 variant | R-HSA-9845621 | 4.937391e-01 | 0.307 | 0 | 0 |
| Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 | R-HSA-5083629 | 4.937391e-01 | 0.307 | 0 | 0 |
| Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 | R-HSA-5083633 | 4.937391e-01 | 0.307 | 0 | 0 |
| Glycogen storage disease type II (GAA) | R-HSA-5357609 | 4.937391e-01 | 0.307 | 0 | 0 |
| Defective F8 cleavage by thrombin | R-HSA-9672391 | 4.937391e-01 | 0.307 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 4.937391e-01 | 0.307 | 0 | 0 |
| ATF6B (ATF6-beta) activates chaperones | R-HSA-8874177 | 4.937391e-01 | 0.307 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 4.948980e-01 | 0.305 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 4.948980e-01 | 0.305 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 4.983550e-01 | 0.302 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 4.983550e-01 | 0.302 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 4.983550e-01 | 0.302 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 5.009161e-01 | 0.300 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 5.013602e-01 | 0.300 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 5.013602e-01 | 0.300 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 5.040280e-01 | 0.298 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 5.040280e-01 | 0.298 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 5.040280e-01 | 0.298 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 5.073022e-01 | 0.295 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 5.073022e-01 | 0.295 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 5.073022e-01 | 0.295 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 5.073022e-01 | 0.295 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 5.073022e-01 | 0.295 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 5.073022e-01 | 0.295 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 5.073022e-01 | 0.295 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 5.073022e-01 | 0.295 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 5.073022e-01 | 0.295 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 5.073022e-01 | 0.295 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 5.082581e-01 | 0.294 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 5.082581e-01 | 0.294 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 5.086322e-01 | 0.294 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 5.106602e-01 | 0.292 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 5.119522e-01 | 0.291 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 5.119522e-01 | 0.291 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 5.119522e-01 | 0.291 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 5.119522e-01 | 0.291 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 5.129192e-01 | 0.290 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 5.129192e-01 | 0.290 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 5.129192e-01 | 0.290 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 5.149731e-01 | 0.288 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 5.149731e-01 | 0.288 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 5.173509e-01 | 0.286 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 5.173509e-01 | 0.286 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 5.193792e-01 | 0.285 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 5.193792e-01 | 0.285 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 5.193792e-01 | 0.285 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 5.211826e-01 | 0.283 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 5.211826e-01 | 0.283 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 5.228258e-01 | 0.282 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 5.243473e-01 | 0.280 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 5.296164e-01 | 0.276 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 5.330019e-01 | 0.273 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 5.431863e-01 | 0.265 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 5.468613e-01 | 0.262 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 5.468613e-01 | 0.262 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 5.468613e-01 | 0.262 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 5.468613e-01 | 0.262 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 5.469437e-01 | 0.262 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 5.469437e-01 | 0.262 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 5.469437e-01 | 0.262 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 5.469437e-01 | 0.262 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 5.469437e-01 | 0.262 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 5.469437e-01 | 0.262 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 5.469437e-01 | 0.262 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 5.469630e-01 | 0.262 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 5.469630e-01 | 0.262 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 5.469630e-01 | 0.262 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 5.469630e-01 | 0.262 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 5.469630e-01 | 0.262 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 5.470981e-01 | 0.262 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 5.471930e-01 | 0.262 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 5.471930e-01 | 0.262 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 5.473004e-01 | 0.262 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 5.473004e-01 | 0.262 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 5.480862e-01 | 0.261 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 5.480862e-01 | 0.261 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 5.480862e-01 | 0.261 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 5.488172e-01 | 0.261 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 5.488172e-01 | 0.261 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 5.495922e-01 | 0.260 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 5.495922e-01 | 0.260 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 5.495922e-01 | 0.260 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 5.524387e-01 | 0.258 | 0 | 0 |
| FGFR4 ligand binding and activation | R-HSA-190322 | 5.524387e-01 | 0.258 | 0 | 0 |
| PDH complex synthesizes acetyl-CoA from PYR | R-HSA-9861559 | 5.524387e-01 | 0.258 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 5.524387e-01 | 0.258 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 5.524387e-01 | 0.258 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 5.524387e-01 | 0.258 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 5.524387e-01 | 0.258 | 0 | 0 |
| Microbial factors inhibit CASP4 activity | R-HSA-9956593 | 5.524387e-01 | 0.258 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 5.524387e-01 | 0.258 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 5.524387e-01 | 0.258 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 5.524387e-01 | 0.258 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 5.582409e-01 | 0.253 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 5.582409e-01 | 0.253 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 5.582409e-01 | 0.253 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 5.582409e-01 | 0.253 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 5.582409e-01 | 0.253 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 5.582409e-01 | 0.253 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 5.582409e-01 | 0.253 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 5.582409e-01 | 0.253 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 5.582409e-01 | 0.253 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 5.582409e-01 | 0.253 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 5.582409e-01 | 0.253 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 5.666048e-01 | 0.247 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 5.675825e-01 | 0.246 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 5.703925e-01 | 0.244 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 5.720991e-01 | 0.243 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 5.720991e-01 | 0.243 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 5.720991e-01 | 0.243 | 0 | 0 |
| Activated NTRK3 signals through PLCG1 | R-HSA-9034793 | 5.729718e-01 | 0.242 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 5.729718e-01 | 0.242 | 0 | 0 |
| Signaling by plasma membrane FGFR1 fusions | R-HSA-8853336 | 5.729718e-01 | 0.242 | 0 | 0 |
| Defective CYP7B1 causes SPG5A and CBAS3 | R-HSA-5579013 | 5.729718e-01 | 0.242 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 5.729718e-01 | 0.242 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 5.729718e-01 | 0.242 | 0 | 0 |
| Defective SLC7A7 causes lysinuric protein intolerance (LPI) | R-HSA-5660862 | 5.729718e-01 | 0.242 | 0 | 0 |
| Signalling to STAT3 | R-HSA-198745 | 5.729718e-01 | 0.242 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 5.729718e-01 | 0.242 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 5.729718e-01 | 0.242 | 0 | 0 |
| Type II Na+/Pi cotransporters | R-HSA-427589 | 5.729718e-01 | 0.242 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 5.729718e-01 | 0.242 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 5.729718e-01 | 0.242 | 0 | 0 |
| FasL/ CD95L signaling | R-HSA-75157 | 5.729718e-01 | 0.242 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 5.744705e-01 | 0.241 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 5.778483e-01 | 0.238 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 5.778483e-01 | 0.238 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 5.778483e-01 | 0.238 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 5.814342e-01 | 0.235 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 5.814342e-01 | 0.235 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 5.814342e-01 | 0.235 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 5.818486e-01 | 0.235 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 5.823685e-01 | 0.235 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 5.824550e-01 | 0.235 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 5.828654e-01 | 0.234 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 5.828654e-01 | 0.234 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 5.828654e-01 | 0.234 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 5.834398e-01 | 0.234 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 5.908516e-01 | 0.229 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 5.908516e-01 | 0.229 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 5.908582e-01 | 0.229 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 5.908582e-01 | 0.229 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 5.908582e-01 | 0.229 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 5.933585e-01 | 0.227 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 5.933585e-01 | 0.227 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 5.933585e-01 | 0.227 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 5.965774e-01 | 0.224 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 6.013369e-01 | 0.221 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 6.027933e-01 | 0.220 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 6.053076e-01 | 0.218 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 6.053076e-01 | 0.218 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 6.053076e-01 | 0.218 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 6.053076e-01 | 0.218 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 6.053076e-01 | 0.218 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 6.053076e-01 | 0.218 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 6.053076e-01 | 0.218 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 6.053076e-01 | 0.218 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 6.065353e-01 | 0.217 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 6.073211e-01 | 0.217 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 6.090334e-01 | 0.215 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 6.120247e-01 | 0.213 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 6.146711e-01 | 0.211 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 6.146711e-01 | 0.211 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 6.146711e-01 | 0.211 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 6.146711e-01 | 0.211 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 6.146711e-01 | 0.211 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 6.149278e-01 | 0.211 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 6.150828e-01 | 0.211 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 6.164635e-01 | 0.210 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 6.202686e-01 | 0.207 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 6.203176e-01 | 0.207 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 6.224415e-01 | 0.206 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 6.224415e-01 | 0.206 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 6.226398e-01 | 0.206 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 6.254174e-01 | 0.204 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 6.257959e-01 | 0.204 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 6.270780e-01 | 0.203 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 6.270780e-01 | 0.203 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 6.270780e-01 | 0.203 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 6.270780e-01 | 0.203 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 6.308588e-01 | 0.200 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 6.334900e-01 | 0.198 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 6.340670e-01 | 0.198 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 6.340670e-01 | 0.198 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 6.373892e-01 | 0.196 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 6.373892e-01 | 0.196 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 6.383962e-01 | 0.195 | 0 | 0 |
| betaKlotho-mediated ligand binding | R-HSA-1307965 | 6.398080e-01 | 0.194 | 0 | 0 |
| Nucleotide catabolism defects | R-HSA-9735786 | 6.398080e-01 | 0.194 | 0 | 0 |
| Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine | R-HSA-9735763 | 6.398080e-01 | 0.194 | 0 | 0 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | R-HSA-2644607 | 6.398080e-01 | 0.194 | 0 | 0 |
| FBXW7 Mutants and NOTCH1 in Cancer | R-HSA-2644605 | 6.398080e-01 | 0.194 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 6.398080e-01 | 0.194 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 6.398080e-01 | 0.194 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 6.398080e-01 | 0.194 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 6.398080e-01 | 0.194 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 6.398080e-01 | 0.194 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 6.398080e-01 | 0.194 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 6.403417e-01 | 0.194 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 6.407898e-01 | 0.193 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 6.432688e-01 | 0.192 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 6.436288e-01 | 0.191 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 6.437956e-01 | 0.191 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 6.449221e-01 | 0.190 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 6.449221e-01 | 0.190 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 6.484665e-01 | 0.188 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 6.484665e-01 | 0.188 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 6.484665e-01 | 0.188 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 6.484665e-01 | 0.188 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 6.484665e-01 | 0.188 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 6.484665e-01 | 0.188 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 6.506990e-01 | 0.187 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 6.506990e-01 | 0.187 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 6.533781e-01 | 0.185 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 6.538578e-01 | 0.185 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 6.538578e-01 | 0.185 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 6.540539e-01 | 0.184 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 6.575983e-01 | 0.182 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 6.583701e-01 | 0.182 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 6.610243e-01 | 0.180 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 6.610243e-01 | 0.180 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 6.610243e-01 | 0.180 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 6.610243e-01 | 0.180 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 6.610243e-01 | 0.180 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 6.610243e-01 | 0.180 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 6.610243e-01 | 0.180 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 6.653898e-01 | 0.177 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 6.653898e-01 | 0.177 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 6.674772e-01 | 0.176 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 6.735615e-01 | 0.172 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 6.735615e-01 | 0.172 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 6.741595e-01 | 0.171 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 6.741595e-01 | 0.171 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 6.741595e-01 | 0.171 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 6.783814e-01 | 0.169 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 6.786178e-01 | 0.168 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 6.790431e-01 | 0.168 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 6.854428e-01 | 0.164 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 6.854428e-01 | 0.164 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 6.854428e-01 | 0.164 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 6.854428e-01 | 0.164 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 6.854428e-01 | 0.164 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 6.866487e-01 | 0.163 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 6.866487e-01 | 0.163 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 6.877878e-01 | 0.163 | 0 | 0 |
| FGFR2b ligand binding and activation | R-HSA-190377 | 6.877878e-01 | 0.163 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 6.877878e-01 | 0.163 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 6.877878e-01 | 0.163 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 6.877878e-01 | 0.163 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 6.877878e-01 | 0.163 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 6.877878e-01 | 0.163 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 6.877878e-01 | 0.163 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 6.906899e-01 | 0.161 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 6.906971e-01 | 0.161 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 6.926721e-01 | 0.159 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 6.926721e-01 | 0.159 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 6.926721e-01 | 0.159 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 6.926721e-01 | 0.159 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 6.926721e-01 | 0.159 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 6.926721e-01 | 0.159 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 6.926721e-01 | 0.159 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 6.940438e-01 | 0.159 | 1 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 6.961865e-01 | 0.157 | 0 | 0 |
| FGFR1c and Klotho ligand binding and activation | R-HSA-190374 | 6.961865e-01 | 0.157 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 6.961865e-01 | 0.157 | 0 | 0 |
| Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA) | R-HSA-5619067 | 6.961865e-01 | 0.157 | 0 | 0 |
| Defective SLC1A3 causes episodic ataxia 6 (EA6) | R-HSA-5619062 | 6.961865e-01 | 0.157 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 6.961865e-01 | 0.157 | 0 | 0 |
| Toxicity of botulinum toxin type G (botG) | R-HSA-5250989 | 6.961865e-01 | 0.157 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 6.961865e-01 | 0.157 | 0 | 0 |
| Suppression of autophagy | R-HSA-9636569 | 6.961865e-01 | 0.157 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 6.961865e-01 | 0.157 | 0 | 0 |
| Biosynthesis of DPAn-3-derived 13-series resolvins | R-HSA-9026403 | 6.961865e-01 | 0.157 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 6.961865e-01 | 0.157 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 6.961865e-01 | 0.157 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 6.961865e-01 | 0.157 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 6.961865e-01 | 0.157 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 6.961865e-01 | 0.157 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 6.965837e-01 | 0.157 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 6.965837e-01 | 0.157 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 6.965837e-01 | 0.157 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 6.981080e-01 | 0.156 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 6.981080e-01 | 0.156 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 7.005590e-01 | 0.155 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 7.005590e-01 | 0.155 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 7.005590e-01 | 0.155 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 7.005590e-01 | 0.155 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 7.018169e-01 | 0.154 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 7.092199e-01 | 0.149 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 7.092199e-01 | 0.149 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 7.164386e-01 | 0.145 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 7.189665e-01 | 0.143 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 7.220365e-01 | 0.141 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 7.220365e-01 | 0.141 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 7.220365e-01 | 0.141 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 7.220365e-01 | 0.141 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 7.234154e-01 | 0.141 | 0 | 0 |
| Endosomal/Vacuolar pathway | R-HSA-1236977 | 7.234154e-01 | 0.141 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 7.234154e-01 | 0.141 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 7.234154e-01 | 0.141 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 7.234154e-01 | 0.141 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 7.234154e-01 | 0.141 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 7.234154e-01 | 0.141 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 7.234154e-01 | 0.141 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 7.259078e-01 | 0.139 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 7.317044e-01 | 0.136 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 7.339440e-01 | 0.134 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 7.347653e-01 | 0.134 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 7.382543e-01 | 0.132 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 7.437432e-01 | 0.129 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 7.437432e-01 | 0.129 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 7.437432e-01 | 0.129 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 7.437432e-01 | 0.129 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 7.437432e-01 | 0.129 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 7.437432e-01 | 0.129 | 0 | 0 |
| Defective CSF2RA causes SMDP4 | R-HSA-5688890 | 7.437432e-01 | 0.129 | 0 | 0 |
| Defective CSF2RB causes SMDP5 | R-HSA-5688849 | 7.437432e-01 | 0.129 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 7.437432e-01 | 0.129 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 7.437432e-01 | 0.129 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 7.437432e-01 | 0.129 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 7.437432e-01 | 0.129 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 7.437432e-01 | 0.129 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 7.437432e-01 | 0.129 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 7.437432e-01 | 0.129 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 7.437432e-01 | 0.129 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 7.437432e-01 | 0.129 | 0 | 0 |
| Threonine catabolism | R-HSA-8849175 | 7.437432e-01 | 0.129 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 7.437432e-01 | 0.129 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 7.437432e-01 | 0.129 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 7.437432e-01 | 0.129 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 7.448303e-01 | 0.128 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 7.491640e-01 | 0.125 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 7.491640e-01 | 0.125 | 0 | 0 |
| Biosynthesis of Lipoxins (LX) | R-HSA-2142700 | 7.491640e-01 | 0.125 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 7.491640e-01 | 0.125 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 7.496204e-01 | 0.125 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 7.496204e-01 | 0.125 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 7.496204e-01 | 0.125 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 7.496204e-01 | 0.125 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 7.515123e-01 | 0.124 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 7.528989e-01 | 0.123 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 7.555420e-01 | 0.122 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 7.555420e-01 | 0.122 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 7.555420e-01 | 0.122 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 7.555420e-01 | 0.122 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 7.555420e-01 | 0.122 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 7.555420e-01 | 0.122 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 7.555420e-01 | 0.122 | 0 | 0 |
| Diseases associated with surfactant metabolism | R-HSA-5687613 | 7.555420e-01 | 0.122 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 7.555420e-01 | 0.122 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 7.555420e-01 | 0.122 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 7.555420e-01 | 0.122 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 7.574907e-01 | 0.121 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 7.574907e-01 | 0.121 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 7.586177e-01 | 0.120 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 7.684461e-01 | 0.114 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 7.715848e-01 | 0.113 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 7.717258e-01 | 0.113 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 7.717258e-01 | 0.113 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 7.717258e-01 | 0.113 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 7.717258e-01 | 0.113 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 7.717258e-01 | 0.113 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 7.717402e-01 | 0.113 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 7.741258e-01 | 0.111 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 7.741258e-01 | 0.111 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 7.741258e-01 | 0.111 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 7.756689e-01 | 0.110 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 7.837793e-01 | 0.106 | 0 | 0 |
| Defective B4GALT1 causes B4GALT1-CDG (CDG-2d) | R-HSA-3656244 | 7.838580e-01 | 0.106 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 7.838580e-01 | 0.106 | 0 | 0 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | R-HSA-9912529 | 7.838580e-01 | 0.106 | 0 | 0 |
| Defective CHST14 causes EDS, musculocontractural type | R-HSA-3595174 | 7.838580e-01 | 0.106 | 0 | 0 |
| Defective CHST6 causes MCDC1 | R-HSA-3656225 | 7.838580e-01 | 0.106 | 0 | 0 |
| Defective ST3GAL3 causes MCT12 and EIEE15 | R-HSA-3656243 | 7.838580e-01 | 0.106 | 0 | 0 |
| Defective CHST3 causes SEDCJD | R-HSA-3595172 | 7.838580e-01 | 0.106 | 0 | 0 |
| Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) | R-HSA-5619070 | 7.838580e-01 | 0.106 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 7.838580e-01 | 0.106 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 7.838580e-01 | 0.106 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 7.838580e-01 | 0.106 | 0 | 0 |
| Defective factor VIII causes hemophilia A | R-HSA-9662001 | 7.838580e-01 | 0.106 | 0 | 0 |
| Metabolism of vitamin K | R-HSA-6806664 | 7.838580e-01 | 0.106 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 7.838580e-01 | 0.106 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 7.838580e-01 | 0.106 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 7.838580e-01 | 0.106 | 0 | 0 |
| FGFR2c ligand binding and activation | R-HSA-190375 | 7.843906e-01 | 0.105 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 7.843906e-01 | 0.105 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 7.843906e-01 | 0.105 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 7.843906e-01 | 0.105 | 0 | 0 |
| Signaling by activated point mutants of FGFR3 | R-HSA-1839130 | 7.843906e-01 | 0.105 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 7.843906e-01 | 0.105 | 0 | 0 |
| FGFR3 mutant receptor activation | R-HSA-2033514 | 7.843906e-01 | 0.105 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 7.843906e-01 | 0.105 | 0 | 0 |
| Immune System | R-HSA-168256 | 7.858890e-01 | 0.105 | 1 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 7.922662e-01 | 0.101 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 7.922662e-01 | 0.101 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 7.970115e-01 | 0.099 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 7.970115e-01 | 0.099 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 7.970115e-01 | 0.099 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 7.970115e-01 | 0.099 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 7.970115e-01 | 0.099 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 8.057963e-01 | 0.094 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 8.093649e-01 | 0.092 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 8.102001e-01 | 0.091 | 0 | 0 |
| FGFR3c ligand binding and activation | R-HSA-190372 | 8.102001e-01 | 0.091 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 8.102001e-01 | 0.091 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 8.102001e-01 | 0.091 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 8.102001e-01 | 0.091 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 8.102001e-01 | 0.091 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 8.102001e-01 | 0.091 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 8.102988e-01 | 0.091 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 8.112947e-01 | 0.091 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 8.176951e-01 | 0.087 | 0 | 0 |
| Progressive trimming of alpha-1,2-linked mannose residues from Man9/8/7GlcNAc2 to produce Man5GlcNAc2 | R-HSA-964827 | 8.176951e-01 | 0.087 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 8.176951e-01 | 0.087 | 0 | 0 |
| FGFR3b ligand binding and activation | R-HSA-190371 | 8.176951e-01 | 0.087 | 0 | 0 |
| Defective CHSY1 causes TPBS | R-HSA-3595177 | 8.176951e-01 | 0.087 | 0 | 0 |
| DAG1 core M1 glycosylations | R-HSA-8932506 | 8.176951e-01 | 0.087 | 0 | 0 |
| Cysteine formation from homocysteine | R-HSA-1614603 | 8.176951e-01 | 0.087 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 8.176951e-01 | 0.087 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 8.176951e-01 | 0.087 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 8.176951e-01 | 0.087 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 8.176951e-01 | 0.087 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 8.176951e-01 | 0.087 | 0 | 0 |
| Biosynthesis of maresin conjugates in tissue regeneration (MCTR) | R-HSA-9026762 | 8.176951e-01 | 0.087 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 8.176951e-01 | 0.087 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 8.179234e-01 | 0.087 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 8.179234e-01 | 0.087 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 8.179234e-01 | 0.087 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 8.244153e-01 | 0.084 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 8.251885e-01 | 0.083 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 8.294341e-01 | 0.081 | 1 | 1 |
| RSV-host interactions | R-HSA-9833110 | 8.304472e-01 | 0.081 | 1 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 8.332148e-01 | 0.079 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 8.332148e-01 | 0.079 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 8.332148e-01 | 0.079 | 0 | 0 |
| FGFR3 ligand binding and activation | R-HSA-190239 | 8.332148e-01 | 0.079 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 8.332148e-01 | 0.079 | 0 | 0 |
| Transport and metabolism of PAPS | R-HSA-174362 | 8.332148e-01 | 0.079 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 8.332148e-01 | 0.079 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 8.332148e-01 | 0.079 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 8.369730e-01 | 0.077 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 8.376939e-01 | 0.077 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 8.381776e-01 | 0.077 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 8.381776e-01 | 0.077 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 8.382906e-01 | 0.077 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 8.382906e-01 | 0.077 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 8.422007e-01 | 0.075 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 8.450660e-01 | 0.073 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 8.452630e-01 | 0.073 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 8.462366e-01 | 0.073 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 8.462366e-01 | 0.073 | 0 | 0 |
| DAG1 core M2 glycosylations | R-HSA-8932504 | 8.462366e-01 | 0.073 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 8.462366e-01 | 0.073 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 8.462366e-01 | 0.073 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 8.462366e-01 | 0.073 | 0 | 0 |
| Toxicity of botulinum toxin type B (botB) | R-HSA-5250958 | 8.462366e-01 | 0.073 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 8.462366e-01 | 0.073 | 0 | 0 |
| Nucleotide salvage defects | R-HSA-9734207 | 8.462366e-01 | 0.073 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 8.462366e-01 | 0.073 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 8.462366e-01 | 0.073 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 8.462366e-01 | 0.073 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 8.462366e-01 | 0.073 | 0 | 0 |
| RSK activation | R-HSA-444257 | 8.462366e-01 | 0.073 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 8.513028e-01 | 0.070 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 8.513922e-01 | 0.070 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 8.536772e-01 | 0.069 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 8.536772e-01 | 0.069 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 8.536772e-01 | 0.069 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 8.536772e-01 | 0.069 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 8.536772e-01 | 0.069 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 8.536772e-01 | 0.069 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 8.536772e-01 | 0.069 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 8.542764e-01 | 0.068 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 8.542764e-01 | 0.068 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 8.543376e-01 | 0.068 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 8.673227e-01 | 0.062 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 8.680931e-01 | 0.061 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 8.685798e-01 | 0.061 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 8.699519e-01 | 0.061 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 8.699519e-01 | 0.061 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 8.699519e-01 | 0.061 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 8.703111e-01 | 0.060 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 8.703111e-01 | 0.060 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 8.703111e-01 | 0.060 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 8.703111e-01 | 0.060 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 8.703111e-01 | 0.060 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 8.703111e-01 | 0.060 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 8.703111e-01 | 0.060 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 8.718221e-01 | 0.060 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 8.718221e-01 | 0.060 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 8.718221e-01 | 0.060 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 8.718221e-01 | 0.060 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 8.718221e-01 | 0.060 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 8.718221e-01 | 0.060 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 8.718221e-01 | 0.060 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 8.718221e-01 | 0.060 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 8.718221e-01 | 0.060 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 8.718221e-01 | 0.060 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 8.735892e-01 | 0.059 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 8.735892e-01 | 0.059 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 8.813429e-01 | 0.055 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 8.878735e-01 | 0.052 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 8.878735e-01 | 0.052 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 8.878735e-01 | 0.052 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 8.878735e-01 | 0.052 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 8.903734e-01 | 0.050 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 8.904862e-01 | 0.050 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 8.906174e-01 | 0.050 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 8.906174e-01 | 0.050 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 8.906174e-01 | 0.050 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 8.906174e-01 | 0.050 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 8.906174e-01 | 0.050 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 8.906174e-01 | 0.050 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 8.906174e-01 | 0.050 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 8.906174e-01 | 0.050 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 8.906174e-01 | 0.050 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 8.906174e-01 | 0.050 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 8.906174e-01 | 0.050 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 8.906174e-01 | 0.050 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 8.956699e-01 | 0.048 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 8.956699e-01 | 0.048 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 8.968895e-01 | 0.047 | 0 | 0 |
| PKA activation | R-HSA-163615 | 9.020421e-01 | 0.045 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 9.020421e-01 | 0.045 | 0 | 0 |
| Activated point mutants of FGFR2 | R-HSA-2033519 | 9.020421e-01 | 0.045 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 9.020421e-01 | 0.045 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.020421e-01 | 0.045 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 9.020421e-01 | 0.045 | 0 | 0 |
| DAG1 core M3 glycosylations | R-HSA-8932505 | 9.077452e-01 | 0.042 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 9.077452e-01 | 0.042 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 9.077452e-01 | 0.042 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 9.077452e-01 | 0.042 | 0 | 0 |
| Hormone ligand-binding receptors | R-HSA-375281 | 9.077452e-01 | 0.042 | 0 | 0 |
| Cholesterol biosynthesis via desmosterol | R-HSA-6807047 | 9.077452e-01 | 0.042 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 9.077452e-01 | 0.042 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 9.077452e-01 | 0.042 | 0 | 0 |
| Biosynthesis of DPAn-3-derived maresins | R-HSA-9026290 | 9.077452e-01 | 0.042 | 0 | 0 |
| Inorganic anion exchange by SLC26 transporters | R-HSA-427601 | 9.077452e-01 | 0.042 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 9.077452e-01 | 0.042 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 9.077452e-01 | 0.042 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 9.077452e-01 | 0.042 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.078298e-01 | 0.042 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 9.083796e-01 | 0.042 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.103555e-01 | 0.041 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.145238e-01 | 0.039 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 9.145238e-01 | 0.039 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.145238e-01 | 0.039 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.145238e-01 | 0.039 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 9.145238e-01 | 0.039 | 0 | 0 |
| Synthesis of 5-eicosatetraenoic acids | R-HSA-2142688 | 9.145238e-01 | 0.039 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 9.145238e-01 | 0.039 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.164801e-01 | 0.038 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.172604e-01 | 0.038 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 9.172604e-01 | 0.038 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 9.172604e-01 | 0.038 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.179223e-01 | 0.037 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 9.184500e-01 | 0.037 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 9.186958e-01 | 0.037 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 9.186958e-01 | 0.037 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 9.186958e-01 | 0.037 | 0 | 0 |
| DS-GAG biosynthesis | R-HSA-2022923 | 9.221918e-01 | 0.035 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 9.221918e-01 | 0.035 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 9.221918e-01 | 0.035 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 9.221918e-01 | 0.035 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 9.254995e-01 | 0.034 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 9.254995e-01 | 0.034 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.254995e-01 | 0.034 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.256241e-01 | 0.034 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 9.262860e-01 | 0.033 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 9.279403e-01 | 0.032 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 9.279403e-01 | 0.032 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 9.343769e-01 | 0.029 | 0 | 0 |
| Biosynthesis of DPAn-3-derived protectins and resolvins | R-HSA-9026286 | 9.343769e-01 | 0.029 | 0 | 0 |
| Maple Syrup Urine Disease | R-HSA-9865114 | 9.343769e-01 | 0.029 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 9.343769e-01 | 0.029 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 9.343769e-01 | 0.029 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 9.343769e-01 | 0.029 | 0 | 0 |
| FGFR2 ligand binding and activation | R-HSA-190241 | 9.351346e-01 | 0.029 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 9.351346e-01 | 0.029 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 9.351346e-01 | 0.029 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 9.351346e-01 | 0.029 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 9.351346e-01 | 0.029 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 9.351346e-01 | 0.029 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 9.351346e-01 | 0.029 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 9.362095e-01 | 0.029 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 9.388628e-01 | 0.027 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.393107e-01 | 0.027 | 1 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.399753e-01 | 0.027 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 9.407593e-01 | 0.027 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.423568e-01 | 0.026 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.423568e-01 | 0.026 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 9.435797e-01 | 0.025 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 9.435797e-01 | 0.025 | 0 | 0 |
| Metabolism of Angiotensinogen to Angiotensins | R-HSA-2022377 | 9.435797e-01 | 0.025 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 9.435940e-01 | 0.025 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 9.435940e-01 | 0.025 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.435940e-01 | 0.025 | 0 | 0 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | R-HSA-5676594 | 9.446543e-01 | 0.025 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 9.446543e-01 | 0.025 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.448746e-01 | 0.025 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 9.459229e-01 | 0.024 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 9.459229e-01 | 0.024 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 9.486929e-01 | 0.023 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.501777e-01 | 0.022 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.509713e-01 | 0.022 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 9.509713e-01 | 0.022 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 9.509713e-01 | 0.022 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.513320e-01 | 0.022 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.521963e-01 | 0.021 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 9.533227e-01 | 0.021 | 0 | 0 |
| N-glycan trimming and elongation in the cis-Golgi | R-HSA-964739 | 9.533227e-01 | 0.021 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 9.533227e-01 | 0.021 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 9.533227e-01 | 0.021 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 9.533227e-01 | 0.021 | 0 | 0 |
| Biosynthesis of E-series 18(R)-resolvins | R-HSA-9023661 | 9.533227e-01 | 0.021 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 9.533227e-01 | 0.021 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 9.533227e-01 | 0.021 | 0 | 0 |
| Formation of the active cofactor, UDP-glucuronate | R-HSA-173599 | 9.533227e-01 | 0.021 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 9.533227e-01 | 0.021 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 9.533227e-01 | 0.021 | 0 | 0 |
| Biosynthesis of protectin and resolvin conjugates in tissue regeneration (PCTR and RCTR) | R-HSA-9026766 | 9.533227e-01 | 0.021 | 0 | 0 |
| Ciprofloxacin ADME | R-HSA-9793528 | 9.533227e-01 | 0.021 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 9.533227e-01 | 0.021 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 9.533227e-01 | 0.021 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 9.543010e-01 | 0.020 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.551909e-01 | 0.020 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.562443e-01 | 0.019 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.572331e-01 | 0.019 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 9.574321e-01 | 0.019 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 9.574321e-01 | 0.019 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.602152e-01 | 0.018 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 9.606338e-01 | 0.017 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 9.606338e-01 | 0.017 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 9.606338e-01 | 0.017 | 0 | 0 |
| Protein repair | R-HSA-5676934 | 9.606338e-01 | 0.017 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 9.606338e-01 | 0.017 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 9.606338e-01 | 0.017 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 9.606338e-01 | 0.017 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.612488e-01 | 0.017 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.623677e-01 | 0.017 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.623784e-01 | 0.017 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.624791e-01 | 0.017 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.647347e-01 | 0.016 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 9.658740e-01 | 0.015 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 9.658740e-01 | 0.015 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 9.658740e-01 | 0.015 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.663510e-01 | 0.015 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 9.665125e-01 | 0.015 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 9.668001e-01 | 0.015 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 9.668001e-01 | 0.015 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 9.668001e-01 | 0.015 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 9.679903e-01 | 0.014 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 9.679903e-01 | 0.014 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 9.679903e-01 | 0.014 | 0 | 0 |
| Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives | R-HSA-9027604 | 9.679903e-01 | 0.014 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.679903e-01 | 0.014 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.689890e-01 | 0.014 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 9.699746e-01 | 0.013 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.699746e-01 | 0.013 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.716830e-01 | 0.012 | 0 | 0 |
| Heme assimilation | R-HSA-9927020 | 9.720008e-01 | 0.012 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 9.720008e-01 | 0.012 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 9.720008e-01 | 0.012 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 9.720008e-01 | 0.012 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 9.720008e-01 | 0.012 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 9.722741e-01 | 0.012 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.722741e-01 | 0.012 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.722741e-01 | 0.012 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.722741e-01 | 0.012 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 9.722741e-01 | 0.012 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.736739e-01 | 0.012 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 9.760016e-01 | 0.011 | 0 | 0 |
| Biosynthesis of DPAn-3 SPMs | R-HSA-9025094 | 9.760016e-01 | 0.011 | 0 | 0 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | R-HSA-83936 | 9.760016e-01 | 0.011 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 9.760016e-01 | 0.011 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.760016e-01 | 0.011 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.760016e-01 | 0.011 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 9.763069e-01 | 0.010 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 9.763871e-01 | 0.010 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 9.763871e-01 | 0.010 | 0 | 0 |
| Biosynthesis of aspirin-triggered D-series resolvins | R-HSA-9020265 | 9.763871e-01 | 0.010 | 0 | 0 |
| Synthesis of 15-eicosatetraenoic acid derivatives | R-HSA-2142770 | 9.763871e-01 | 0.010 | 0 | 0 |
| GDP-fucose biosynthesis | R-HSA-6787639 | 9.763871e-01 | 0.010 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 9.763871e-01 | 0.010 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.768173e-01 | 0.010 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.772360e-01 | 0.010 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.780972e-01 | 0.010 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.781762e-01 | 0.010 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 9.791912e-01 | 0.009 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 9.792419e-01 | 0.009 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 9.792419e-01 | 0.009 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.796546e-01 | 0.009 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.800000e-01 | 0.009 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 9.800864e-01 | 0.009 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 9.800864e-01 | 0.009 | 0 | 0 |
| Biosynthesis of DHA-derived sulfido conjugates | R-HSA-9026395 | 9.800864e-01 | 0.009 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.802865e-01 | 0.009 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.808561e-01 | 0.008 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.813958e-01 | 0.008 | 0 | 0 |
| Biosynthesis of EPA-derived SPMs | R-HSA-9018679 | 9.820562e-01 | 0.008 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 9.820562e-01 | 0.008 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 9.820562e-01 | 0.008 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.821587e-01 | 0.008 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.822387e-01 | 0.008 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.822387e-01 | 0.008 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.822387e-01 | 0.008 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 9.832064e-01 | 0.007 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 9.832064e-01 | 0.007 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 9.832064e-01 | 0.007 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 9.832064e-01 | 0.007 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 9.843663e-01 | 0.007 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.844984e-01 | 0.007 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.848091e-01 | 0.007 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.855628e-01 | 0.006 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.856352e-01 | 0.006 | 0 | 0 |
| Keratan sulfate degradation | R-HSA-2022857 | 9.858377e-01 | 0.006 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.858377e-01 | 0.006 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.858377e-01 | 0.006 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.861765e-01 | 0.006 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.863107e-01 | 0.006 | 0 | 0 |
| Biosynthesis of DPA-derived SPMs | R-HSA-9018683 | 9.866160e-01 | 0.006 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.872066e-01 | 0.006 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.876167e-01 | 0.005 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.879856e-01 | 0.005 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 9.880568e-01 | 0.005 | 0 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 9.880568e-01 | 0.005 | 0 | 0 |
| Biosynthesis of E-series 18(S)-resolvins | R-HSA-9018896 | 9.880568e-01 | 0.005 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 9.880568e-01 | 0.005 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.880568e-01 | 0.005 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 9.884507e-01 | 0.005 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 9.884507e-01 | 0.005 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.886145e-01 | 0.005 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.887103e-01 | 0.005 | 1 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.887281e-01 | 0.005 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.894552e-01 | 0.005 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 9.895258e-01 | 0.005 | 0 | 0 |
| CS-GAG biosynthesis | R-HSA-2022870 | 9.899284e-01 | 0.004 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 9.899284e-01 | 0.004 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 9.899284e-01 | 0.004 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.900392e-01 | 0.004 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.900507e-01 | 0.004 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.905798e-01 | 0.004 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.914135e-01 | 0.004 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.914135e-01 | 0.004 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.914877e-01 | 0.004 | 0 | 0 |
| Biosynthesis of D-series resolvins | R-HSA-9018676 | 9.915067e-01 | 0.004 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.915067e-01 | 0.004 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 9.915067e-01 | 0.004 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.915067e-01 | 0.004 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.919660e-01 | 0.004 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.922644e-01 | 0.003 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.922644e-01 | 0.003 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 9.926019e-01 | 0.003 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.926019e-01 | 0.003 | 0 | 0 |
| Phosphate bond hydrolysis by NUDT proteins | R-HSA-2393930 | 9.926019e-01 | 0.003 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 9.926019e-01 | 0.003 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 9.928378e-01 | 0.003 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.928378e-01 | 0.003 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.928378e-01 | 0.003 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.928378e-01 | 0.003 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.928946e-01 | 0.003 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.930237e-01 | 0.003 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.936287e-01 | 0.003 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.937093e-01 | 0.003 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.939603e-01 | 0.003 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.939603e-01 | 0.003 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 9.939603e-01 | 0.003 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.940011e-01 | 0.003 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 9.945155e-01 | 0.002 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 9.945155e-01 | 0.002 | 0 | 0 |
| Beta-oxidation of pristanoyl-CoA | R-HSA-389887 | 9.949069e-01 | 0.002 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.949069e-01 | 0.002 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.952808e-01 | 0.002 | 0 | 0 |
| Linoleic acid (LA) metabolism | R-HSA-2046105 | 9.957053e-01 | 0.002 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 9.957053e-01 | 0.002 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.958736e-01 | 0.002 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.958736e-01 | 0.002 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.959411e-01 | 0.002 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 9.959752e-01 | 0.002 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.961397e-01 | 0.002 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.963785e-01 | 0.002 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.963785e-01 | 0.002 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.965103e-01 | 0.002 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.965103e-01 | 0.002 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.967840e-01 | 0.001 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 9.969462e-01 | 0.001 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.969462e-01 | 0.001 | 0 | 0 |
| Iron assimilation using enterobactin | R-HSA-9638334 | 9.969462e-01 | 0.001 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.969462e-01 | 0.001 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.969526e-01 | 0.001 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.970062e-01 | 0.001 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.972418e-01 | 0.001 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.974234e-01 | 0.001 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.974250e-01 | 0.001 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.975257e-01 | 0.001 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.977873e-01 | 0.001 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.981003e-01 | 0.001 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.981003e-01 | 0.001 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.981003e-01 | 0.001 | 0 | 0 |
| Aspartate and asparagine metabolism | R-HSA-8963693 | 9.981691e-01 | 0.001 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.983829e-01 | 0.001 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.984178e-01 | 0.001 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 9.984562e-01 | 0.001 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.984781e-01 | 0.001 | 1 | 0 |
| Neddylation | R-HSA-8951664 | 9.984891e-01 | 0.001 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.984970e-01 | 0.001 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.986013e-01 | 0.001 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 9.986983e-01 | 0.001 | 0 | 0 |
| Keratan sulfate biosynthesis | R-HSA-2022854 | 9.986983e-01 | 0.001 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.987454e-01 | 0.001 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.987472e-01 | 0.001 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.987556e-01 | 0.001 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.988003e-01 | 0.001 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.988658e-01 | 0.000 | 0 | 0 |
| CS/DS degradation | R-HSA-2024101 | 9.989024e-01 | 0.000 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 9.989024e-01 | 0.000 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.991183e-01 | 0.000 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.991481e-01 | 0.000 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.991481e-01 | 0.000 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.991694e-01 | 0.000 | 0 | 0 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | R-HSA-2408508 | 9.992197e-01 | 0.000 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.992197e-01 | 0.000 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.992197e-01 | 0.000 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.993069e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.993421e-01 | 0.000 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.993527e-01 | 0.000 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.993527e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.993611e-01 | 0.000 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.993611e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.993670e-01 | 0.000 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.994296e-01 | 0.000 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 9.994453e-01 | 0.000 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.994453e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.994453e-01 | 0.000 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.995902e-01 | 0.000 | 0 | 0 |
| Diseases associated with N-glycosylation of proteins | R-HSA-3781860 | 9.996057e-01 | 0.000 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 9.996675e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.997100e-01 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.997146e-01 | 0.000 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.997197e-01 | 0.000 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.997224e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.997327e-01 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.997547e-01 | 0.000 | 1 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.997691e-01 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.998129e-01 | 0.000 | 0 | 0 |
| Pyrimidine catabolism | R-HSA-73621 | 9.998320e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.998460e-01 | 0.000 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.998514e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.998585e-01 | 0.000 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 9.998640e-01 | 0.000 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.998640e-01 | 0.000 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.998837e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.998894e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.998906e-01 | 0.000 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.999213e-01 | 0.000 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.999245e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.999286e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.999312e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999312e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.999371e-01 | 0.000 | 0 | 0 |
| Keratan sulfate/keratin metabolism | R-HSA-1638074 | 9.999397e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.999474e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999476e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.999543e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999560e-01 | 0.000 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.999571e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.999615e-01 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.999615e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999664e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.999664e-01 | 0.000 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.999710e-01 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.999715e-01 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.999715e-01 | 0.000 | 0 | 0 |
| Glucuronidation | R-HSA-156588 | 9.999743e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.999748e-01 | 0.000 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.999782e-01 | 0.000 | 0 | 0 |
| Chondroitin sulfate/dermatan sulfate metabolism | R-HSA-1793185 | 9.999784e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999788e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.999796e-01 | 0.000 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.999796e-01 | 0.000 | 0 | 0 |
| Metal ion assimilation from the host | R-HSA-9638482 | 9.999796e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.999796e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.999799e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.999818e-01 | 0.000 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.999852e-01 | 0.000 | 0 | 0 |
| Transport of vitamins, nucleosides, and related molecules | R-HSA-425397 | 9.999874e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.999874e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999900e-01 | 0.000 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.999908e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.999926e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999926e-01 | 0.000 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.999933e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.999953e-01 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.999955e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999975e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.999984e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999995e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999996e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999996e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.999996e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 9.999997e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.999998e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999998e-01 | 0.000 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.999999e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 1.000000e+00 | 0.000 | 0 | 0 |
| Scavenging of heme from plasma | R-HSA-2168880 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 1.000000e+00 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 1.000000e+00 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000e+00 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 1.000000e+00 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 1.000000e+00 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 1.000000e+00 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000e+00 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 1.000000e+00 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | -0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | -0.000 | 0 | 0 |